WO2016097869A1 - Fused ring heteroaryl compounds and their use as trk inhibitors - Google Patents
Fused ring heteroaryl compounds and their use as trk inhibitors Download PDFInfo
- Publication number
- WO2016097869A1 WO2016097869A1 PCT/IB2015/002521 IB2015002521W WO2016097869A1 WO 2016097869 A1 WO2016097869 A1 WO 2016097869A1 IB 2015002521 W IB2015002521 W IB 2015002521W WO 2016097869 A1 WO2016097869 A1 WO 2016097869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mmol
- chemical compound
- formula
- additional embodiments
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 21
- 239000003112 inhibitor Substances 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 366
- -1 polymorph Chemical class 0.000 claims abstract description 96
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 208000002193 Pain Diseases 0.000 claims abstract description 16
- 230000036407 pain Effects 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 37
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 34
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 29
- 125000005842 heteroatom Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 17
- 239000011737 fluorine Substances 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical group 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 229940126214 compound 3 Drugs 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 229910052727 yttrium Inorganic materials 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 235000011180 diphosphates Nutrition 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 4
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 229940126657 Compound 17 Drugs 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 229940125782 compound 2 Drugs 0.000 claims description 3
- 229940125851 compound 27 Drugs 0.000 claims description 3
- 229940126540 compound 41 Drugs 0.000 claims description 3
- 239000001177 diphosphate Substances 0.000 claims description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 229940126639 Compound 33 Drugs 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940125773 compound 10 Drugs 0.000 claims description 2
- 229940126142 compound 16 Drugs 0.000 claims description 2
- 229940126208 compound 22 Drugs 0.000 claims description 2
- 229940125961 compound 24 Drugs 0.000 claims description 2
- 229940127204 compound 29 Drugs 0.000 claims description 2
- 229940125877 compound 31 Drugs 0.000 claims description 2
- 229940125807 compound 37 Drugs 0.000 claims description 2
- 229940127573 compound 38 Drugs 0.000 claims description 2
- 229940125844 compound 46 Drugs 0.000 claims description 2
- 229940127113 compound 57 Drugs 0.000 claims description 2
- 229940009662 edetate Drugs 0.000 claims description 2
- 229950000206 estolate Drugs 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 229940050411 fumarate Drugs 0.000 claims description 2
- 229960001731 gluceptate Drugs 0.000 claims description 2
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 229940001447 lactate Drugs 0.000 claims description 2
- 229940099584 lactobionate Drugs 0.000 claims description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229940102396 methyl bromide Drugs 0.000 claims description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims 1
- 229940127007 Compound 39 Drugs 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 229940126086 compound 21 Drugs 0.000 claims 1
- 229940125833 compound 23 Drugs 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 229940125878 compound 36 Drugs 0.000 claims 1
- 229940125936 compound 42 Drugs 0.000 claims 1
- 229940125900 compound 59 Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 177
- 201000011510 cancer Diseases 0.000 abstract description 112
- 239000000651 prodrug Substances 0.000 abstract description 32
- 229940002612 prodrug Drugs 0.000 abstract description 32
- 150000002148 esters Chemical class 0.000 abstract description 29
- 239000012453 solvate Substances 0.000 abstract description 27
- 230000004770 neurodegeneration Effects 0.000 abstract description 4
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 396
- 235000019439 ethyl acetate Nutrition 0.000 description 198
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 192
- 239000000203 mixture Substances 0.000 description 186
- 239000007787 solid Substances 0.000 description 169
- 239000011541 reaction mixture Substances 0.000 description 164
- 239000000243 solution Substances 0.000 description 153
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 134
- 239000011734 sodium Substances 0.000 description 125
- 238000004440 column chromatography Methods 0.000 description 108
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 104
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 100
- 238000005160 1H NMR spectroscopy Methods 0.000 description 99
- 239000012267 brine Substances 0.000 description 85
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 85
- 239000012044 organic layer Substances 0.000 description 84
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 65
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 58
- 239000000543 intermediate Substances 0.000 description 51
- 125000004432 carbon atom Chemical group C* 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 238000005481 NMR spectroscopy Methods 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 229920006395 saturated elastomer Polymers 0.000 description 40
- 230000002829 reductive effect Effects 0.000 description 39
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 38
- 238000002360 preparation method Methods 0.000 description 36
- 239000003814 drug Substances 0.000 description 35
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 34
- 238000001914 filtration Methods 0.000 description 32
- 239000007821 HATU Substances 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 30
- 229940124597 therapeutic agent Drugs 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 29
- 229940088598 enzyme Drugs 0.000 description 29
- 239000008194 pharmaceutical composition Substances 0.000 description 27
- 0 C*C(*)(C*C1)N1C1=NC2=C(C=C(*(C)C)C(N(*)*)=O)C=NCC2C(C)C=C1 Chemical compound C*C(*)(C*C1)N1C1=NC2=C(C=C(*(C)C)C(N(*)*)=O)C=NCC2C(C)C=C1 0.000 description 26
- 239000003921 oil Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 23
- 230000035755 proliferation Effects 0.000 description 23
- 230000012010 growth Effects 0.000 description 22
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 21
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 20
- 238000000746 purification Methods 0.000 description 18
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000004429 atom Chemical group 0.000 description 15
- 101150111783 NTRK1 gene Proteins 0.000 description 14
- 238000011374 additional therapy Methods 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 229940034982 antineoplastic agent Drugs 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 108010025020 Nerve Growth Factor Proteins 0.000 description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 101150117329 NTRK3 gene Proteins 0.000 description 9
- 101150056950 Ntrk2 gene Proteins 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- 208000027866 inflammatory disease Diseases 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 8
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 description 8
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 206010038389 Renal cancer Diseases 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 201000010982 kidney cancer Diseases 0.000 description 8
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 8
- PWQLYPCPQHHIEQ-UHFFFAOYSA-N 2,2-dimethylpropanehydrazide;hydrochloride Chemical compound Cl.CC(C)(C)C(=O)NN PWQLYPCPQHHIEQ-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 238000003149 assay kit Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 229940053128 nerve growth factor Drugs 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- BFKYQYMHJANOTR-UHFFFAOYSA-N 2h-pyrimidine-1-carbonitrile Chemical compound N#CN1CN=CC=C1 BFKYQYMHJANOTR-UHFFFAOYSA-N 0.000 description 6
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 6
- 239000002168 alkylating agent Substances 0.000 description 6
- 229940100198 alkylating agent Drugs 0.000 description 6
- 230000000340 anti-metabolite Effects 0.000 description 6
- 230000000118 anti-neoplastic effect Effects 0.000 description 6
- 229940100197 antimetabolite Drugs 0.000 description 6
- 239000002256 antimetabolite Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 6
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 6
- 230000003394 haemopoietic effect Effects 0.000 description 6
- 239000000367 immunologic factor Substances 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 125000002456 taxol group Chemical group 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 6
- NCXSNNVYILYEBC-SNVBAGLBSA-N (2r)-2-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=CC=C(F)C([C@@H]2NCCC2)=C1 NCXSNNVYILYEBC-SNVBAGLBSA-N 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
- NCXSNNVYILYEBC-UHFFFAOYSA-N 2-(2,5-difluorophenyl)pyrrolidine Chemical compound FC1=CC=C(F)C(C2NCCC2)=C1 NCXSNNVYILYEBC-UHFFFAOYSA-N 0.000 description 5
- 101150018711 AASS gene Proteins 0.000 description 5
- 238000003043 HTRF KinEASE-TK Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229910002666 PdCl2 Inorganic materials 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 230000003388 anti-hormonal effect Effects 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 229960001467 bortezomib Drugs 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000003966 growth inhibitor Substances 0.000 description 5
- 230000003054 hormonal effect Effects 0.000 description 5
- 230000003463 hyperproliferative effect Effects 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 238000000021 kinase assay Methods 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 5
- SMQYQMQTCFRHEJ-OIBJUYFYSA-N (2r,4s)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine Chemical compound C1[C@H](F)CN[C@H]1C1=CC(F)=CC=C1F SMQYQMQTCFRHEJ-OIBJUYFYSA-N 0.000 description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
- SXMFANICSAKMKM-UHFFFAOYSA-N (propanoylamino)azanium;chloride Chemical compound Cl.CCC(=O)NN SXMFANICSAKMKM-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- NHCNLGHWNHJXBY-UHFFFAOYSA-N 2-methylpropanehydrazide;hydrochloride Chemical compound Cl.CC(C)C(=O)NN NHCNLGHWNHJXBY-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- IYJLJHGSNXDVPN-UHFFFAOYSA-N 5-fluoro-2-methoxy-3-pyrrolidin-2-ylpyridine Chemical compound COC1=NC=C(F)C=C1C1NCCC1 IYJLJHGSNXDVPN-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010039710 Scleroderma Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 229910000365 copper sulfate Inorganic materials 0.000 description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- BFBMDIKDROEXQH-UHFFFAOYSA-N cyclopropanecarbohydrazide;hydrochloride Chemical compound Cl.NNC(=O)C1CC1 BFBMDIKDROEXQH-UHFFFAOYSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- GJJYYMXBCYYXPQ-UHFFFAOYSA-N tert-butyl 2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- SMQYQMQTCFRHEJ-XVKPBYJWSA-N (2S,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidine Chemical compound FC1=C(C=C(C=C1)F)[C@H]1NC[C@H](C1)F SMQYQMQTCFRHEJ-XVKPBYJWSA-N 0.000 description 3
- MSGGHUGYEWOYEE-LVSKKATPSA-N (NZ,S)-N-[4-chloro-1-(2,5-difluorophenyl)butylidene]-2-methylpropane-2-sulfinamide Chemical compound ClCCC/C(/C1=C(C=CC(=C1)F)F)=N/[S@@](=O)C(C)(C)C MSGGHUGYEWOYEE-LVSKKATPSA-N 0.000 description 3
- QDAJHTQUEOFGCL-SECBINFHSA-N 3-fluoro-5-[(2r)-pyrrolidin-2-yl]pyridine Chemical compound FC1=CN=CC([C@@H]2NCCC2)=C1 QDAJHTQUEOFGCL-SECBINFHSA-N 0.000 description 3
- QDAJHTQUEOFGCL-UHFFFAOYSA-N 3-fluoro-5-pyrrolidin-2-ylpyridine Chemical compound FC1=CN=CC(C2NCCC2)=C1 QDAJHTQUEOFGCL-UHFFFAOYSA-N 0.000 description 3
- PIFJQRCPUURIFV-UHFFFAOYSA-N 4-azidooxane Chemical compound [N-]=[N+]=NC1CCOCC1 PIFJQRCPUURIFV-UHFFFAOYSA-N 0.000 description 3
- MCKOYDSNCWNCHG-UHFFFAOYSA-N 4-chloro-1-(2,5-difluorophenyl)butan-1-one Chemical compound FC1=CC=C(F)C(C(=O)CCCCl)=C1 MCKOYDSNCWNCHG-UHFFFAOYSA-N 0.000 description 3
- FSLPJGQYYJWHAB-UHFFFAOYSA-N 4-chloro-1-(5-fluoropyridin-3-yl)butan-1-one Chemical compound FC1=CN=CC(C(=O)CCCCl)=C1 FSLPJGQYYJWHAB-UHFFFAOYSA-N 0.000 description 3
- QIZHVCUPPAMGIW-UHFFFAOYSA-N 5-(2,5-difluorophenyl)-3,4-dihydro-2h-pyrrole Chemical compound FC1=CC=C(F)C(C=2CCCN=2)=C1 QIZHVCUPPAMGIW-UHFFFAOYSA-N 0.000 description 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 125000004990 dihydroxyalkyl group Chemical group 0.000 description 3
- 230000001842 fibrogenetic effect Effects 0.000 description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 201000006334 interstitial nephritis Diseases 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 208000011379 keloid formation Diseases 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 3
- JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 description 3
- 125000003367 polycyclic group Polymers 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 3
- BRNQETRAMMATCR-UHFFFAOYSA-N tert-butyl 3-azidopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N=[N+]=[N-])C1 BRNQETRAMMATCR-UHFFFAOYSA-N 0.000 description 3
- WLAZHMYDLUILKR-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(OS(C)(=O)=O)C1 WLAZHMYDLUILKR-UHFFFAOYSA-N 0.000 description 3
- NSIPUSRSFSTUKD-UHFFFAOYSA-N tert-butyl 4-(2-azidoacetyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)CN=[N+]=[N-])CC1 NSIPUSRSFSTUKD-UHFFFAOYSA-N 0.000 description 3
- SWUCHJAQBNXPBO-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-methylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C)(O)CC1 SWUCHJAQBNXPBO-UHFFFAOYSA-N 0.000 description 3
- ZQSOYUYQHRGXAA-UHFFFAOYSA-N tert-butyl N-(propanoylamino)carbamate Chemical compound CCC(=O)NNC(=O)OC(C)(C)C ZQSOYUYQHRGXAA-UHFFFAOYSA-N 0.000 description 3
- QUXRUQHCVUUDHV-UHFFFAOYSA-N tert-butyl N-[4-(2,5-difluorophenyl)-4-oxobutyl]carbamate Chemical compound FC1=C(C=C(C=C1)F)C(CCCNC(OC(C)(C)C)=O)=O QUXRUQHCVUUDHV-UHFFFAOYSA-N 0.000 description 3
- IDVFHPOILGGHAA-UHFFFAOYSA-N tert-butyl N-[4-(5-fluoropyridin-3-yl)-4-oxobutyl]carbamate Chemical compound FC=1C=C(C=NC=1)C(CCCNC(OC(C)(C)C)=O)=O IDVFHPOILGGHAA-UHFFFAOYSA-N 0.000 description 3
- CFXLEMZNWBHNQV-UHFFFAOYSA-N tert-butyl n-(2,2-dimethylpropanoylamino)carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)C(C)(C)C CFXLEMZNWBHNQV-UHFFFAOYSA-N 0.000 description 3
- KOGKSDLPRCIHAK-UHFFFAOYSA-N tert-butyl n-(2-methylpropanoylamino)carbamate Chemical compound CC(C)C(=O)NNC(=O)OC(C)(C)C KOGKSDLPRCIHAK-UHFFFAOYSA-N 0.000 description 3
- RUSQVAKYNDQLGV-UHFFFAOYSA-N tert-butyl n-(cyclopropanecarbonylamino)carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)C1CC1 RUSQVAKYNDQLGV-UHFFFAOYSA-N 0.000 description 3
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011135 tin Substances 0.000 description 3
- 229910052718 tin Inorganic materials 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- BEVGOGJIDJYUNN-MRVPVSSYSA-N (4r)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidin-2-one Chemical compound CC(C)(C)[Si](C)(C)O[C@H]1CNC(=O)C1 BEVGOGJIDJYUNN-MRVPVSSYSA-N 0.000 description 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
- QKNSGUCCNZBAAJ-UHFFFAOYSA-N 1-o,4-o-ditert-butyl 2-o-methyl piperazine-1,2,4-tricarboxylate Chemical compound COC(=O)C1CN(C(=O)OC(C)(C)C)CCN1C(=O)OC(C)(C)C QKNSGUCCNZBAAJ-UHFFFAOYSA-N 0.000 description 2
- LHGHFWIPMSPGDT-UHFFFAOYSA-N 3-(3,4-dihydro-2H-pyrrol-5-yl)-5-fluoro-2-methoxypyridine Chemical compound N=1CCCC=1C=1C(=NC=C(C=1)F)OC LHGHFWIPMSPGDT-UHFFFAOYSA-N 0.000 description 2
- HNNNBQRRIHKFLI-UHFFFAOYSA-N 3-bromo-5-fluoropyridine Chemical compound FC1=CN=CC(Br)=C1 HNNNBQRRIHKFLI-UHFFFAOYSA-N 0.000 description 2
- MYSFVARIFHFNGF-UHFFFAOYSA-N 4-(5-fluoro-2-methoxypyridin-3-yl)but-3-yn-1-amine Chemical compound FC=1C=C(C(=NC=1)OC)C#CCCN MYSFVARIFHFNGF-UHFFFAOYSA-N 0.000 description 2
- CXBLQEIODBBSQD-UHFFFAOYSA-N 4-methylpiperidin-4-ol Chemical compound CC1(O)CCNCC1 CXBLQEIODBBSQD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012094 cell viability reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004212 difluorophenyl group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ASPAKSDHNNXVIB-LLVKDONJSA-N tert-butyl (4r)-4-[tert-butyl(dimethyl)silyl]oxy-2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C[C@H](O[Si](C)(C)C(C)(C)C)CC1=O ASPAKSDHNNXVIB-LLVKDONJSA-N 0.000 description 2
- IKEDNWKXANROGX-UHFFFAOYSA-N tert-butyl 3-azidopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N=[N+]=[N-])C1 IKEDNWKXANROGX-UHFFFAOYSA-N 0.000 description 2
- KWQRKOSMSFLBTJ-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)C1 KWQRKOSMSFLBTJ-UHFFFAOYSA-N 0.000 description 2
- JLIKTOWFNQDEME-UHFFFAOYSA-N tert-butyl 4-(hydrazinecarbonyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(=O)NN)CC1 JLIKTOWFNQDEME-UHFFFAOYSA-N 0.000 description 2
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- IOGISYQVOGVIEU-UHFFFAOYSA-N (-4-Hydroxy-2-pyrrolidone Natural products OC1CNC(=O)C1 IOGISYQVOGVIEU-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KNGQIERPRIBUMA-YJYMSZOUSA-N (2r)-1-[(s)-tert-butylsulfinyl]-2-(2,5-difluorophenyl)pyrrolidine Chemical compound CC(C)(C)[S@](=O)N1CCC[C@@H]1C1=CC(F)=CC=C1F KNGQIERPRIBUMA-YJYMSZOUSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- DIIFZCPZIRQDIJ-UHFFFAOYSA-N (3,5-dimethyl-1,2-oxazol-4-yl)boronic acid Chemical compound CC1=NOC(C)=C1B(O)O DIIFZCPZIRQDIJ-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- IOGISYQVOGVIEU-GSVOUGTGSA-N (4r)-4-hydroxypyrrolidin-2-one Chemical compound O[C@H]1CNC(=O)C1 IOGISYQVOGVIEU-GSVOUGTGSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- MZQJNAZFJATCHT-ZZXKWVIFSA-N (E)-3-[5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound FC1=C(C=C(C=C1)F)C1N(CCC1)C1=NC=2N(C=C1)N=CC=2/C=C/C(=O)O MZQJNAZFJATCHT-ZZXKWVIFSA-N 0.000 description 1
- UGXHNRFYNOJJGC-GTVARFKMSA-N (NZ,S)-N-[4-chloro-1-(5-fluoropyridin-3-yl)butylidene]-2-methylpropane-2-sulfinamide Chemical compound ClCCC/C(/C=1C=NC=C(C=1)F)=N/[S@@](=O)C(C)(C)C UGXHNRFYNOJJGC-GTVARFKMSA-N 0.000 description 1
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
- HANPIZQMFCWPKY-UHFFFAOYSA-N 1,2-oxazol-4-ylboronic acid Chemical compound OB(O)C=1C=NOC=1 HANPIZQMFCWPKY-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- CAFROQYMUICGNO-UHFFFAOYSA-N 2,2,2-trifluoroethyl formate Chemical compound FC(F)(F)COC=O CAFROQYMUICGNO-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- UFZKDGBPXYBWPQ-UHFFFAOYSA-N 2-(1,4-ditert-butylpiperazin-2-yl)propan-2-ol Chemical compound C(C)(C)(C)N1CC(N(CC1)C(C)(C)C)C(C)(C)O UFZKDGBPXYBWPQ-UHFFFAOYSA-N 0.000 description 1
- GSVGWLPTOCOYMX-UHFFFAOYSA-N 2-[4-(5-fluoro-2-methoxypyridin-3-yl)but-3-ynyl]isoindole-1,3-dione Chemical compound FC=1C=C(C(=NC=1)OC)C#CCCN1C(C2=CC=CC=C2C1=O)=O GSVGWLPTOCOYMX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LXSIAVSHFKCGPI-UHFFFAOYSA-N 2-tert-butyl-5-[5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-1,3,4-oxadiazole Chemical compound C(C)(C)(C)C=1OC(=NN=1)C=1C=NN2C=1N=C(C=C2)N1C(CCC1)C=1C=NC=C(C=1)F LXSIAVSHFKCGPI-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- DGFCOTYVOPMDCX-UHFFFAOYSA-N 3-(3,4-dihydro-2H-pyrrol-5-yl)-5-fluoropyridine Chemical compound N=1CCCC=1C=1C=NC=C(C=1)F DGFCOTYVOPMDCX-UHFFFAOYSA-N 0.000 description 1
- HSWCOAGQYSBFAK-UHFFFAOYSA-N 3-bromo-5-fluoro-2-methoxypyridine Chemical compound COC1=NC=C(F)C=C1Br HSWCOAGQYSBFAK-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- QHFMHHCERKSNIF-UHFFFAOYSA-N 3-methylsulfonyloxypyrrolidine-1-carboxylic acid Chemical compound CS(=O)(=O)OC1CCN(C(O)=O)C1 QHFMHHCERKSNIF-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UZZLKMWBNSGUTE-UHFFFAOYSA-N 4-(2-azidoacetyl)piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCN(CC1)C(=O)CN=[N+]=[N-] UZZLKMWBNSGUTE-UHFFFAOYSA-N 0.000 description 1
- OTYOBNBVRQAUCH-UHFFFAOYSA-N 4-chloro-n-methoxy-n-methylbutanamide Chemical compound CON(C)C(=O)CCCCl OTYOBNBVRQAUCH-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- OHZUEFKOZYWUFF-UHFFFAOYSA-N 4-hydroxypiperidine-1-carboxylic acid Chemical compound OC1CCN(C(O)=O)CC1 OHZUEFKOZYWUFF-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- SYGIIIFQNSTTQB-OAHLLOKOSA-N 5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbaldehyde Chemical compound FC1=C(C=C(C=C1)F)[C@@H]1N(CCC1)C1=NC=2N(C=C1)N=CC=2C=O SYGIIIFQNSTTQB-OAHLLOKOSA-N 0.000 description 1
- OQMVDSDNBRDESX-UHFFFAOYSA-N 5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-(5-methyl-1H-1,2,4-triazol-3-yl)pyrazolo[1,5-a]pyrimidine Chemical compound FC1=C(C=C(C=C1)F)C1N(CCC1)C1=NC=2N(C=C1)N=CC=2C1=NNC(=N1)C OQMVDSDNBRDESX-UHFFFAOYSA-N 0.000 description 1
- SCZPNICJEULVKY-UHFFFAOYSA-N 5-[2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound N=1C2=C(C(=O)O)C=NN2C=CC=1N1CCCC1C1=CC(F)=CC=C1F SCZPNICJEULVKY-UHFFFAOYSA-N 0.000 description 1
- OYGONYREIXSORZ-UHFFFAOYSA-N 5-chloropyrazolo[1,5-a]pyrimidine-3-carbonitrile Chemical compound N1=C(Cl)C=CN2N=CC(C#N)=C21 OYGONYREIXSORZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 206010003253 Arthritis enteropathic Diseases 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 101710129634 Beta-nerve growth factor Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- JEMYVVTXDXPIAZ-JTQLQIEISA-N C=C(CCC1)C[C@H]1c1cc(F)cnc1 Chemical compound C=C(CCC1)C[C@H]1c1cc(F)cnc1 JEMYVVTXDXPIAZ-JTQLQIEISA-N 0.000 description 1
- LOXXMOTZUMSESZ-CYBJTIMGSA-N CC(C)(C)[S@](N(CCC1)[C@H]1C(C(C=C1)F)C=C1F)=O Chemical compound CC(C)(C)[S@](N(CCC1)[C@H]1C(C(C=C1)F)C=C1F)=O LOXXMOTZUMSESZ-CYBJTIMGSA-N 0.000 description 1
- UCXNNVHWTLTTDV-SECBINFHSA-N CCCC[C@@H](C)c(cc(cc1)F)c1I Chemical compound CCCC[C@@H](C)c(cc(cc1)F)c1I UCXNNVHWTLTTDV-SECBINFHSA-N 0.000 description 1
- YZVWVIHXBZWHJX-UHFFFAOYSA-N CCc(cc1)cc(C(CCC2)N2C(C=CCc2cnc3)=Nc2c3-c2cnc[o]2)c1F Chemical compound CCc(cc1)cc(C(CCC2)N2C(C=CCc2cnc3)=Nc2c3-c2cnc[o]2)c1F YZVWVIHXBZWHJX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100328463 Mus musculus Cmya5 gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- XHQYBDSXTDXSHY-UHFFFAOYSA-N Semicarbazide hydrochloride Chemical compound Cl.NNC(N)=O XHQYBDSXTDXSHY-UHFFFAOYSA-N 0.000 description 1
- 229910020169 SiOa Inorganic materials 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000019667 acute articular rheumatism Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000004983 autoimmune atherosclerosis Diseases 0.000 description 1
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 208000025255 bacterial arthritis Diseases 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- YOMWYEITAAOYEC-UHFFFAOYSA-N butane-2-sulfinamide Chemical compound CCC(C)S(N)=O YOMWYEITAAOYEC-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- ITQFPVUDTFABDH-AATRIKPKSA-N ethyl (e)-3-ethoxyprop-2-enoate Chemical compound CCO\C=C\C(=O)OCC ITQFPVUDTFABDH-AATRIKPKSA-N 0.000 description 1
- OAWHMSXGBFMFTL-UHFFFAOYSA-N ethyl 5-[2-(5-fluoropyridin-3-yl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound N=1C2=C(C(=O)OCC)C=NN2C=CC=1N1CCCC1C1=CN=CC(F)=C1 OAWHMSXGBFMFTL-UHFFFAOYSA-N 0.000 description 1
- YPXGHKWOJXQLQU-UHFFFAOYSA-N ethyl 5-amino-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1N YPXGHKWOJXQLQU-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- UFFSXJKVKBQEHC-UHFFFAOYSA-N heptafluorobutyric anhydride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)C(F)(F)F UFFSXJKVKBQEHC-UHFFFAOYSA-N 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- KADXVMRYQRCLAH-UHFFFAOYSA-N n'-iodobutanediamide Chemical compound NC(=O)CCC(=O)NI KADXVMRYQRCLAH-UHFFFAOYSA-N 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- GSEZHCLWHDZJAB-UHFFFAOYSA-N oxan-4-yl methanesulfonate Chemical compound CS(=O)(=O)OC1CCOCC1 GSEZHCLWHDZJAB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000005616 oxoacid group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- VCZDXEIQUDHMHO-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound C1=CC=NC2=C=C[N]N21 VCZDXEIQUDHMHO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- AFHQSQTUSWXNCL-UHFFFAOYSA-N pyrimidin-5-ol Chemical compound OC1=CN=CN=C1.OC1=CN=CN=C1 AFHQSQTUSWXNCL-UHFFFAOYSA-N 0.000 description 1
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 1
- APCBTRDHCDOPNY-UHFFFAOYSA-N tert-butyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)C1 APCBTRDHCDOPNY-UHFFFAOYSA-N 0.000 description 1
- WOEQSXAIPTXOPY-UHFFFAOYSA-N tert-butyl 4-methylsulfonyloxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)CC1 WOEQSXAIPTXOPY-UHFFFAOYSA-N 0.000 description 1
- UDCCOLDRWMCMFI-NNJIEVJOSA-N tert-butyl N-[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-4-(2,5-difluorophenyl)-4-hydroxybutyl]carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNC(OC(C)(C)C)=O)CC(O)C1=C(C=CC(=C1)F)F UDCCOLDRWMCMFI-NNJIEVJOSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- This disclosure relates to new chemical entities and use of the entities as TRK inhibitors.
- Trk's are high affinity tyrosine kinase receptors that are activated by Neurotrophins (NT).
- the Trk receptor family has three members: TrkA, TrkB and TrkC.
- TrkA soluble growth factors Nerve Growth Factor
- BDNF Brain-Derived Neurotrophic Factor
- NT-4/5 Neurotrophin-3
- TrkC Neurotrophin-3 TrkC.
- Trk's are widely expressed in neuronal tissue and are implicated in the maintenance, signaling and survival of neuronal cells (Patapoutian, A. eta!., Current Opinion in Neurobiology, 2001, 11, 272-280).
- Inhibitors of the Trk neutrophin pathway have been demonstrated to be effective in numerous pre-e inical animal models of pain.
- Antagonistic NGF and TrkA antibodies have been shown to be efficacious in inflammatory and neuropathic pain animal models and in human clinical trials.
- NGF secreted by tumor cells and tumor invading macrophages directly stimulates TrkA located on peripheral pain fibers.
- Using various tumor models in both mice and rats it was demonstrated that neutralizing NGF with a monoclonal antibody inhibits cancer related pain to a degree similar or superior to the highest tolerated dose of morphine.
- Activation of the BDNF/TrkB pathway has been implicated in numerous studies as a modulator of marious types of pain including inflammatory pain ( atayoshi, S., J. Physiol. 2005, 569:685-695), neuropathic pain (Thompson, S.W. Proc. Natl. Acad. Sci.
- TrkA and TrkB kinases may serve as a mediator of NGF driven biological responses, inhibitors of TrkA and/or other Trk kinases may provide an effective treatment for chronic pain states.
- Trk kinases The association between overexpression, activation, amplification and/or mutation of Trk kinases and several cancers as seen with studies conduct on neui blastoma (Brodeur, G.M Nat. Rev. Cancer 2003, 3, 203-216), ovarian cancer (Kruettgen et al. Brain Pathology 2006, 75:304-310), prostate cancer (Dionne et al. Clin. Cancer Res. 1998, 4(8), 1887-1898), pancreatic cancer (Dang et al. j of Gastroenterology ami Hepatology 2006, 27(5), 850-858), large cell neuroendocrine tumors (Marchetti et al. Human Mutation 2008, 29(5), 609-616), and colorectal cancer (Bardeiii, A.
- TrkA, B and C were efficacious in both inhibiting tumor growth and stopping tumor metastasis (Nakagawara, A. Cancer Letters 2001, 759:107-114; Meyer, J. et al. Leukemia 2007, 1-10; Pierottia, M.A. and Greco A. Cancer Letters, 2006, 232:90-98; Eric Adriaenssens, E. et ai. Cancer Res 2008, 68(2), 346-351).
- Recent literature has identified new gene fusions in patients with lung cancer harboring the kinase domain of the NTRK1 gene that encodes the high-affinity nerve growth factor receptor-TrkA. protein (Vaishnavi, A. et. al. Nature Medisine 2013, 79(11), 1469-1472).
- the present application discloses new chemical entities. These new chemical entities can work Trk inhibitors and are believed to be useful in the treatment of multiple types of acute and chrome pain including but not limited to inflammatory pain, neuropathic pain, and pain associated with cancer, surgery and bone fracture. The compounds are also believed to be useful in the treatment of cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
- One aspect of the invention provides a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof:
- R of Formula I is a phenyl ring optionally substituted with one or more substituent groups or a 5-6 membered heteroaryl ring optionally substituted with one or more substituent groups, wherein the one or more substituent groups are independently selected from the group consisting of halogen, -CF 3 , -CHF 2 , NH 2 , hydroxyl, linear C1 -C4 alkyl, branched C1-C4 alkyl, linear C1-C4 alkoxy, and branched C1 -C4 alkoxy.
- R 2 is selected from the group consisting of hydrogen, linear C1-C4 alkyl and branched linear C1-C4 alkyl.
- X is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, -CH 2 0-, -CH 2 NH-,
- J is selected from the group consisting of hydrogen, halogen, linear Cl- C6 alkyl and branched C1-C6 alkyl.
- -NR 4 R 5 either forms a 4-7 membered heterocyclic ring or does not form a ring structure, the heterocyiic ring being either heteroaryl or heterocycloalkyl ring.
- the 4-7 membered heterocyclic ring includes an optional second heteroatom in addition to the nitrogen of - R 4 R 5 and is optionally substituted with one or more substituent groups independently selected from the group consisting of linear C1 -C6 alkyl, branched C1-C6 alkyl, hydroxyl, carboxylic acid, linear C1-C4 alkyl carboxylic acid, and branched C1-C4 alkyl carboxylic acid branched.
- R 4 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C1-C6 alkyl
- R s is selected from the group consisting of hydrogen, linear C -C6 alkyl optionally substituted with at least one fluorine or at least one hydroxyl, branched C1-C6 alkyl optionally substituted with at least one fluorine or at least one hydroxyl, and C1 -C6 cycloalkyl optionally substituted with at least one fluorine or at least one hydroxvl.
- Y 1 , Y , Y°, and Y are each independently selected from the group consisting of -CH, N, O, S, -CR°, and -NR 6 , wherein R (> is selected from the group consisting of hydrogen, linear C1-C4 alkyl, branched C1-C4 alkyl, 5-6 membered aiyl ring, 5-6 membered heteroaryl ring, 3-7 membered heterocycloalkyl ring, 3- 7 membered cycloalkyl ring, -NHCO-(aryl ring), and -CH 2 CO-(C3-C6 membered heterocylic ring).
- R ! of Formula I is a 6-membered aryl or heteroaryl ring optionally substituted with one or more substituent groups independently selected from the group consisting of halogen, hydroxyl, linear C1-C4 alkyl, branched C1-C4 alkyl, linear C1-C4 alkoxy, and branched Cl- C4 alkoxy.
- R 3 is hydrogen or halogen.
- - R 4 R 5 either forms a 4-7 membered heterocyclic ring or does not form a ring structure, the heterocylic ring being either heteroaryl or heterocycloalkyl ring.
- the 4-7 membered heterocyclic ring includes an optional second heteroatom in addition to the nitrogen of -NR 4 R 5 and is optionally substituted with one or more substituent groups independently selected from the group consisting of linear C1-C6 alky], branched C1-C6 alkyl, hydroxyl, carboxytic acid, linear C1-C4 alkyl carboxyhc acid, and branched C1-C4 alkyl carboxylic acid branched.
- R 4 is selected from the group consisting of hydrogen, linear Cl- C6 alkyl and branched C1-C6 alkyl
- R J is selected from the group consisting of hydrogen, linear C1-C6 alkyl optionally substituted with at least one fluorine or at least one hydroxyl, branched C1-C6 alkyi optionally substituted with at least one fluorine or at least one hydroxyl, and C1-C6 cycloalkyl optionally substituted with at least one fluorine or at least one hydroxyl.
- Y l , Y 2 , Y°, and Y 4 are each independently selected from the group consisting of -CH, N, O, S, -CR 6 , and -NR.”, wherein R 6 is selected from the group consisting of hydrogen, linear C1-C4 alkyl, branched C1-C4 alkyi, 5-6 membered aryl ring, 5-6 membered heteroaryl ring, 3-7 membered heterocycloalkyl ring, 3- 7 membered cycloalkyl ring, -NHCO-(aryl ring), and -CH 2 CO-(C3-C6 membered heterocylic ring).
- R 1 a phenyl ring substituted with one or more substituent groups may be independently selected from the group consisting of fluorine, methoxy and ethoxy;
- R 2 and R J are H;
- R 3 may be selected from the group consisting of H, methyl, ethyl, iso-propyl, cyclopropyl, t-butyl, methoxyethyl and hydroxyethyl.
- R 1 may be a pyridine ring substituted with at least one selected from the group consisting of fluorine and niethoxy; R and R' are H; R 3 may be selected from the group consisting of H, methyl, ethyl, iso-propyl, cyclopropyl, t-butyl, nietlioxyethyl and hydroxyethyl.
- R 3 ⁇ 4 may be a pyrid-2-on-3-yl ring optionally substituted with one or more substituent groups independently selected from the group consisting of halogen and C1-C4 alkyl.
- R is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C1-C6 alkyl
- R 3 is selected from the group consisting of linear C1-C6 fluoroalkyl, branched C1-C6 fiuoroalkyl, linear C1-C6 difluoroalkyl, branched C1-C6 difluoroalkyl, linear C1-C6 trifluoroalkyl, branched C1-C6 trifluoroalkyl, linear C1-C6 hyroxyalkyl, branched C1-C6 hyroxyalkyl, linear C2-C6 difluoroalkyl, and branched C2-C6 difluoroalkyl.
- -NR 4 R 5 forming a 4-7 membered heterocylic ring may be a 4-7 membered heterocycloalkyl ring.
- the second heteroatom in the 4-7 membered heterocyclic ring may be selected from the group consisting of nitrogen, oxygen and sulfur.
- the compound of Formula I is a com ound of Formula II:
- the compound of Formula I is a compound of Fomiula HI:
- the compound of Formula I is a compound of Formula IV:
- the salt of the compound of Formula I may be selected from the group consisting of acetate, benzoate, besylate, biiartrate, bromide, carbonate, chloride, edetate, edisylate, estolate, fumarate, gluceptate, gluconate, hydrobromide, hydrochloride, iodide, lactate, lactobionate, malate, maleate, mandelate, mesylate, methyl bromide, methyl sulfate, mucate, napsylate, nitrate, oxalate, pamoate, phosphate, diphosphate, salicylate, disalicylate, stearate, succinate, sulfate, tartrate, tosylate, trieihiodide, trifluoroacetate and valerate.
- Another aspect of the invention provides a method of treating or prophylaxis of a TRK mediated disease selected from the group consisting of papillary thyroid carcinoma, pancreatic cancer, lung cancer, colon cancer, breast carcinoma, neuroblastoma, pain, cachexia, dermatitis and asthma.
- the method comprises administering a pharmaceutically effective amount of the compound of Formula I or a pharmaceutically acceptable salt thereof to a subject in need of such treatment.
- Still another aspect of the invention provides a method of inhibiting a TRK enzyme.
- the method comprises administering a pharmaceutically effective amount of the compound of Formula I or a pharmaceutically acceptable salt thereof to a subject in need of such inhibition.
- Reactions and purification techniques can be performed e.g., using kits of manufacturer's specifications or as commonly accomplished in the ait or as described herein.
- the foregoing techniques and procedures can be generally performed of conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification.
- groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.
- substituent groups are specified by their conventional chemical Formulas, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left.
- CH 2 .O is equivalent to OCH 2.
- the use of general chemical terms, such as though not limited to "alkyl,” “amine,” “arvL” are equivalent to their optionally substituted forms.
- alkyl as used herein, includes optionally substituted alkyl.
- the compounds presented herein may possess one or more stereocenters and each center may exist in the R or S configuration, or combinations thereof. Likewise, the compounds presented herein may possess one or more double bonds and each may exist in the E (trans) or Z (cis) configuration, or combinations thereof. Presentation of one particular stereoisomer, regioisomer, diastereomer, enantiomer or epimer should be understood to include all possible stereoisomers, regioisomers, diastereomers, enantiomers or epimers and mixtures thereof. Thus, the compounds presented herein include all separate configurational stereoisomeric, regioisomenc, diastereomenc, enantiomeric, and epimenc forms as well as the corresponding mixtures thereof.
- bond refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.
- optionally substituted alkyl means either “aikyl” or “substituted alkyl” as defined below.
- an optionally substituted group may be un-substituted (e.g., CH 2 CH 3 ), fully substituted (e.g., CF 2 CF 3 ), mono-substituted (e.g., ( ⁇ 1 ⁇ ( ' ! or substituted at a level anywhere in-between fully substituted and mono- substituted (e. g.
- substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups, potentially ad infinitum) that are stericaily impractical and/or synthetically non-feasible.
- any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons (except in those instances where macromolecular substituents are clearly intended, e.g., polypeptides, polysaccharides, polyethylene glycols, DNA, RNA and the
- Ci-Cn includes Cj-Ci, Ci ⁇ C 3 , ... Ci ⁇ Cn.
- a group designated as "C 1 -C4" indicates that there are one to four carbon atoms in the moiety, i.e. groups containing 1 carbon atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms, as well as the ranges Ci ⁇ C 2 and Cr-C 3 .
- C1-C4 alkyl indicates that there are one to four carbon atoms in the alky] group, i.e., the alkyl group is selected from among methyl, ethyl, propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, and t-butyl.
- a numerical range such as “1 to 10” refers to each integer in the given range; e.g., "1 to 10 carbon atoms” means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, 6 carbon atoms, 7 carbon atoms, 8 carbon atoms, 9 carbon atoms, or 10 carbon atoms.
- heteroatom or “hetero” as used herein, alone or in combination, refer to an atom other than carbon and hydrogen. Heteroatoms are independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but are not limited to these atoms. When two or more heteroatoms are present, the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from the others.
- alkyl refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms.
- Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-l-propyl, 2-methyi-2-propyi, 2-methyl-l- butyl, 3 -methyl-l-butyl, 2-methyl-3 -butyl, 2,2-dimethyl-l-propyl, 2-methyl-l-pentyl, 3 -methyl- 1 - pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2 -dimethyl-1- butyl, 3,3 -dimethyl-1 -butyl, 2 -ethyl-l-butyl, n-butyl, isobutyi, sec-butyl, t-butyi, n-pentyl, isopentyl, neo- pentyl, tert-amyl and hexy
- a numerical range such as "Cj-Ce alkyl” or "Ci j alkyl” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated.
- alkylene refers to a diradical derived from the above-defined monoradical, alkyl. Examples include, but are not limited to methylene (-( ' ! I . ⁇ ). ethylene (-CH 2 CH 2 ), propylene (-CH 2 CH 2 CH 2 ), isopropylene (-CH(G3 ⁇ 4)CH 2 ) and the like.
- alkenyl refers to an optionally substituted straight- chain, or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms.
- a numerical range such as “C 2 -C 6 alkenyl” or “C 2 _6 alkenyl” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl” where no numerical range is designated.
- alkynyl refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2- butynyl, 1 ,3-butadiynyl and the like.
- a numerical range such as “C 2 -C 6 alkynyl” or “C 2 alkynyl” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl” where no numerical range is designated.
- aliphatic refers to an optionally substituted, straight- chain or branched-chain, non-cyclic, saturated, partially unsaturated, or fully unsaturated nonaroniatic hydrocarbon.
- the term collectively includes alkyl, alkenyl and alkynyl groups.
- heteroalkyl refers to optionally substituted aikyl, aikenyl and alkynyl structures respectively, as described above, in which one or more of the skeletal chain carbon atoms (and any associated hydrogen atoms, as appropriate) are each independently replaced with a heteroatom (i.e. an atom other than carbon, such as though not limited to oxygen, nitrogen, sulfur, silicon, phosphorous, tin or combinations thereof.
- a heteroatom i.e. an atom other than carbon, such as though not limited to oxygen, nitrogen, sulfur, silicon, phosphorous, tin or combinations thereof.
- haloaikyi refers to optionally substituted alkyl, aikenyl and alkynyl groups respectively, as defined above, in which one or more hydrogen atoms is replaced by fluorine, chlorine, bromine or iodine atoms, or combinations thereof.
- halogen atoms that are the same as each another (e.g. difluoromethyl).
- halogen atoms that are not all the same as each other (e.g. 1-chloro-l-fluoro-l- iodoethyl).
- Non-limiting examples of haloaikyi groups are fluoromethyl and bromoethyl.
- a non-limiting example of a haloalkenyl group is bromoethenyl.
- a non-limiting example of a haloalkynyl group is chloroethynyl.
- cycle refers to any covalently closed structure, including alic project, heterocyclic, aromatic, heteroa omatic and poly cyclic fused or non-fused ring systems as described herein. Rings can be optionally substituted. Rings can form part of a fused ring system.
- membered is meant to denote the number of skeletal atoms that constitute the ring.
- cyclohexane, pyridine, pyran and pyrimidine are six-membered rings and cyclopentane, pyrrole, tetrahydrofuran and thiophene are five-membered rings.
- fused refers to cyclic structures in which two or more rings share one or more bonds.
- cycloalkyl refers to an optionally substituted, saturated, hydrocarbon monoradical ring, containing from three to about fifteen ring carbon atoms or from three to about ten ring carbon atoms, though may include additional, non-ring carbon atoms as substituents (e.g. methylcyclopropyl).
- cycloalkyl includes azinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyi, thiepanvl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyndinyl, 2-pyrrolinyl, 3-pyrroiinyl, indolmyl, 2H-pyranyl, 4H-pyranyi, dioxanyl, 1,3-dioxolanyl, pyrazoiinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0 " jhexyl, 3-azabicycio [4.
- the terms also include all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides.
- aromatic refers to a planar, cyclic or polycyclic, ring moiety having a delocalized at-electron system containing 4n+2 n electrons, where n is an integer.
- Aromatic rings can be formed by five, six, seven, eight, nine, or more than nine atoms.
- Aromatics can be optionally substituted and can be monocyclic or fused- ring polycyclic.
- aromatic encompasses both ail carbon containing rings (e.g., phenyl) and those rings containing one or more heteroatoms (e.g., pyridine).
- aryl refers to an optionally substituted aromatic hydrocarbon radical of six to about twenty ring carbon atoms, and includes fused and non- fused aryl rings.
- a fused aryl ring radical contains from two to four fused rings where the ring of attachment is an aryl ring, and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof.
- aryl includes fused and non-fused rings containing from six to about twelve ring carbon atoms, as well as those containing from six to about ten ring carbon atoms.
- a non-limiting example of a single ring aryl group includes phenyl; a fused ring aryl group includes naphthyl, phenanthrenyl, anthracenyl, azulenyl; and a non-fused bi-aryl group includes biphenyl.
- heteroaryl refers to optionally substituted aromatic mono-radicals containing from about five to about twenty skeletal ring atoms, where one or more of the ring atoms is a heteroatom independently selected from among oxygen, nitrogen, sulfur, phosphorous, silicon, selenium and tin but not limited to these atoms and with the proviso that the ring of said group does not contain two adjacent O or S atoms.
- the two or more heteroatoms can be the same as each another, or some or all of the two or more heteroatoms can each be different from die others.
- heteroaryl includes optionally substituted fused and non- fused heteroaryl radicals having at least one heteroatom.
- heteroaryl also includes fused and non-fused heteroaryls having from five to about twelve skeletal ring atoms, as well as those having from five to about ten skeletal ring atoms. Bonding to a heteroaryl group can be via a carbon atom or a heteroatom.
- an imidiazole group may be attached to a parent molecule via any of its carbon atoms (imidazol-2-yl, imidazol-4-yl or imidazol-5- yi), or its nitrogen atoms (imidazol-l-yl or imidazol-3-yl).
- a heteroaryl group may be further substituted via any or all of its carbon atoms, and/or any or ail of its heteroatoms.
- a fused heteroaryl radical may contain from two to four fused rings where the ring of attachment is a heteroaromatic ring and the other individual rings may be alicyclic, heterocyclic, aromatic, heteroaromatic or any combination thereof.
- a non-limiting example of a single ring heteroaryl group includes pyridyl; fused ring heteroaryl groups include benzimidazolyl, quinolinyl, acndinyl; and a non-fused bi-heteroaryl group includes bipyridmyl.
- heteroaryls include, without limitation, furanyl, thienyl, oxazolyl, acridmyl, phenazmyi, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazoiyl, benzothiophenyl, benzoxadiazolyl, benzotriazolyl, imidazoiyl, indolyl, isoxazolyl, isoquinolinyl, indolizinyl, isothiazolyl, isoindolyloxadiazolyl, indazolyl, pyridyl, pyridazyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrazolyl, purinyl, phthalazinyl, pteridinyl, quinolinyl, quinazolinyl, quinoxalinyl, triazolyl, tetra
- heterocyclyl refers collectively to heteroalicyclyl and heteroaryl groups.
- the number of carbon atoms in a heterocycle is indicated (e.g., Ci-Q heterocycle)
- at least one non-carbon atom must be present in the ring.
- Designations such as “Cj-Ce heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring.
- 4-6 membered heterocycle refers to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms).
- those two or more heteroatoms can be the same or different from one another.
- Heterocycles can be optionally substituted.
- Non-aromatic heterocyclic groups include groups having only three atoms in the ring, while aromatic heterocy devis groups must have at least five atoms in the ring. Bonding (i.e.
- aikoxy refers to an alkyl ether radical, O-alkyl, including the groups O-aliphatic and O-carbocycle, wherein the alkyl, aliphatic and carbocycle groups may be optionally substituted, and wherein the terms alkyl, aliphatic and carbocycle are as defined herein.
- aikoxy radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tertbutoxy and the like.
- composition refers to a biologically active compound, optionally mixed with at least one phannaceutically acceptable chemical component, such as, though not limited to carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or exeipients.
- solvate refers to a combination of a compound of this invention with a solvent molecule formed by solvation.
- the solvate refers to a hydrate, i.e., the solvent molecule is a water molecule, the combination of a compound of this invention and water forms a hydrate.
- pharmaceutically acceptable salt refers to salts that retain the biological effectiveness of the free acids and bases of the specified compound and that are not biologically or otherwise undesirable.
- Compounds described herein may possess acidic or basic groups and therefore may react, with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed
- phannaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral or organic acid or an inorganic base, such salts including, acetate, aerylate, adipate, alginate, aspartate, benzoate, benzenesuifonate, bisulfate, bisulfite, bromide, butyrate, butyn-l,4-dioate, camphorate, camphorsulfonate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glu
- metaphosphate methoxybenzoate, methylben- zoate, monohydrogenphosphate, 1-napthalenesulfonate, 2-napthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate undeconate and xylenesulfonate.
- acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts (See examples at Berge et al., J. Pharm. Sci. 1977, 66, 1-19.).
- those compounds described herein which may comprise a free acid group may react with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
- suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation
- ammonia or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
- Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
- bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, IV (Ci 4 alkyi , and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethyiamme, ethylenediamine, ethanoiamine, diethanolamine, piperazine and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they may contain. Water or oil-soluble or dispersible products may be obtained by such quaternization. See, for example, Berge et al, supra.
- polymorph or “polymorphism” as used herein refers to a compound of this invention present in different crystal lattice forms.
- esters refers to a derivative of a compound of this invention derived from an oxoacid group and a hydroxy! group, either one of which can be present at the compound of this invention.
- tautomer refers to an isomer readily interconverted from a compound of this invention by e.g., migration of a hydrogen atom or proton.
- pharmaceutically acceptable derivative or prodrug refers to any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention, which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or a pharmaceutically active metabolite or residue thereof.
- Particularly favored derivati ves or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing orally administered compound to be more readily absorbed into blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system).
- prodrugs of the compounds described herein include, but are not limited to, esters, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyaikyl derivatives, quaternary derivatives of tertiary amines, ⁇ -Mannich bases, Schiff bases, ammo acid conjugates, phosphate esters, metal salts and sulfonate esters.
- Various forms of prodrugs are well known in the art. See for example Design of Prodrugs, Bundgaard, A. Ed., Elseview, 1985 and Method in Enzymology, Widder, K. et al., Ed.; Academic, 1985, vol. 42, p. 309-396; Bundgaard, H.
- prodrugs described herein include, but are not limited to, the following groups and combinations of these groups: amine derived prodrugs: Hydroxy prodrugs include, but are not limited to acyloxyalkyl esters, alkoxyearbonyloxyalkyl esters, alkyl esters, aryl esters and disulfide containing esters.
- Trk inhibitor refers to a compound that exhibits an IC 50 , with respect to Trk activity, of no more than about 100 ⁇ activity, of no more than about 50 ⁇ , as measured in the pan- Trk kinase assay described generally herein.
- IC 50 is that concentration of inhibitor which reduces the activity of an enzyme (e.g., Trk) to half-maximal level.
- Compounds described herein have been discovered to exhibit inhibition against Trk
- Compounds of the present invention preferably exhibit an IQo with respect to Trk of no more than about 10 ⁇ , more preferably, no more than about 5 ⁇ preferably, no more than about 1 ⁇ , and most preferably, not more than about 200 nM, as measured in the Trk kinase assay described herein.
- selective refers to a compound of this invention having a lower IC50 value for a Trk enzyme as compared to any other enzymes (e.g., at least 2, 5, 0 or more-fold lower).
- subject encompasses mammals and non- mammals.
- mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
- non- mammals include, but are not limited to, birds, fish and the like.
- the mammal is a human.
- treat include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition, and are intended to include prophylaxis.
- the terms further include achieving a therapeutic benefit and'or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
- compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
- an “effective amount”, “therapeutically effective amount” or “pharmaceutically effective amount” as used herein, refer to a sufficient amount of at least one agent or compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
- an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease.
- An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.
- administer refers to the methods that may be used to enable delivery of compounds or compositions to the desired site of biological action. These methods include, but are not limited to oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular or infusion), topical and rectal administration.
- parenteral injection including intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular or infusion
- topical and rectal administration Those of skill in the art are familiar with administration techniques that can be employed with the compounds and methods described herein, e.g., as discussed in Goodman and Oilman, The Pharmacological Basis of Therapeutics, current ed; Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa.
- the compounds and compositions described herein are administered orally.
- pharmaceutically acceptable refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compounds described herein, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- carrier refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells or tissues.
- agonist refers to a molecule such as a compound, a drug, an enzyme activator or a hormone modulator which enhances the activity of another molecule or the activity of a receptor site.
- antagonist refers to a molecule such as a compound, a drug, an enzyme inhibitor, or a hormone modulator, which diminishes, or prevents the action of another molecule or the activity of a receptor site.
- module means to interact with a target either directly or indirectly so as to alter the activity of the target, including, by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target,
- module refers to a molecule that interacts with a target either directly or indirectly.
- the interactions include, but are not limited to, the interactions of an agonist and an antagonist.
- enhancement means to increase or prolong either in potency or duration of a desired effect.
- enhancing refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents on a system.
- an “enhancing-effective amount,” as used herein, refers to an amount adequate to enhance the effect of another therapeutic agent in a desired system.
- the term “fixed combination” means that at least one of the compounds described herein, and at least one co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
- non-fixed combination means that at least one of the compounds described herein, and at least one co-agent, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with variable intervening time limits, wherein such administration provides effective levels of the two or more compounds in the body of the patient.
- cocktail therapies e.g. the administration of three or more active ingredients.
- co-administration are meant to encompass administration of the selected therapeutic agenis to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different times.
- the compounds described herein will be co-administered with other agents.
- These terms encompass administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time. They include simultaneous administration in separate compositions, administration at different times in separate compositions, and/or administration in a composition in which both agents are present.
- the compounds of the invention and the other agent (s) are administered in a single composition.
- metabolite refers to a derivative of a compound which is formed when the compound is metabolized.
- active metabolite refers to a biologically active derivative of a compound that is formed when the compound is metabolized.
- metabolized refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism. Tims, enzymes may produce specific structural alterations to a compound. For example, cytochrome P450 catalyzes a variety of oxidative and reductive reactions while undine diphosphate glucuronyltransferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulphydryl groups. Further information on metabolism may be obtained from The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill (1996).
- novel chemical compounds include a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.
- R 1 of Formula I is a phenyl ring optionally substituted with one or more substituent groups or a 5-6 membered heteroaryl ring optionally substituted with one or more substituent groups, wherein the one or more substituent groups are independently selected from the group consisting of halogen, -CF 3 , -CHF 2 , NH 2 , hydroxyl, linear C1-C4 alkyl, branched C1-C4 alkyl, linear C1-C4 alkoxy, and branched C1-C4 alkoxy.
- R " is selected from the group consisting of hydrogen, linear C1 -C4 alkyl and branched linear C1-C4 alkyl.
- X is selected from the group consisting of -CH 2 -, -CH 2 CH 2 -, -CH 2 O-, -CI I Ni l-. -CH 2 N(C1 -C4 alkyl)-, -CH(F)-, -(1 ⁇ , ⁇ . -CH(Cl)-, -CH(OH)-, -CH(OCH 3 )-, -CH(NH 2 )-, or -C(CH 3 ) 2 -.
- R' is selected from the group consisting of hydrogen, halogen, linear C1-C6 alkyl and branched C1-C6 alkyl.
- -NR 4 R 3 either forms a 4-7 membered heterocyclic ring or does not form a ring structure, the heterocylic ring being either heteroaryl or heterocycloalkyl ring.
- the 4-7 membered heterocyclic ring includes an optional second heteroatom in addition to the nitrogen of -NR 4 R 5 and is optionally substituted with one or more substituent groups independently selected from the group consisting of linear C1-C6 alkyl, branched C1-C6 alkyl, hydroxyl, carboxylic acid, linear C1 -C4 alkyl carboxylic acid, and branched C1-C4 alkyl carboxylic acid branched.
- R 4 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C1-C6 alkyl
- R 5 is selected from the group consisting of hydrogen, l inear C1-C6 alkyl optionally substituted with at least one fluorine or at least one hydroxyl, branched C1-C6 alkyl optionally substituted with at least one fluorine or at least one hydroxy!, and C1-C6 cycloalkyl optionally substituted w th at least one fluorine or at least one hydroxy!
- Y , Y ⁇ Y J , and Y are each independently selected from the group consisting of -CH, N, O, S, -CR 6 , and -NR°, wherein R 6 is selected from the group consisting of hydrogen, linear C1-C4 alkyi, branched C1-C4 alkyl, 5-6 membered aiyl ring, 5-6 membered heteroarvl rmg, 3-7 membered lieterocycloalkyl ring, 3-7 membered cycloalkyl rmg, -NHCO-(aryl ring), and -C]3 ⁇ 4CO-(C3-C6 membered heterocylic ring).
- the compo nd of Formula I is a compound of Formula II, III or IV:
- some compounds of Formula I or a pharmaceutically accepiable salt, solvate, polymorph, ester, tautomer or prodrug thereof have a structure wherein,
- Q is 5-6 membered heteroarvl rings including, but are not limited to, the following structures:
- R 3 is selected from methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, ⁇ C(CH 3 ) 2 CH 2 F, -CHCF 2 , CFI 2 CFIF 2 , CF 3 , CH 2 CF 3 and CH(CH 3 )CF 3 .
- R 5 is -(Cl -C6)hydroxyalkyl or [(Cl -C6)alkoxy](Cl - C6)a1ky1-.
- Examples include -CH 2 CH 2 OH, -CH 2 CH 2 CH 2 OH, -CH 2 CH 2 CH 2 CH 2 OH, -CH 2 CH 2 CH 2 CH 2 OH,
- R 3 is -(Cl-C6)hydroxyaikyi or [(Cl-C6)alkoxy](Cl-C6)alkyl- and R is hydrogen.
- R 3 is -(Cl-C6)hydroxyaikyi or [(Cl-C6)alkoxy](Cl-C6)alkyl- and R 4 is -(Cl-C6)alkyl.
- R 3 is -(C2-C6)dihydroxyalkyl. Examples include - CH 2 CH(OH)CH 2 OH, -C(CH3)(CH 2 OH) 2> -CH(CH 2 OH) 2 and -CH(CH 2 OH)(CHOHCH 3 ).
- R 3 is -(C2-C6)dihydroxyalkyl and R 4 is hydrogen.
- R 3 is - (C2-C6)dihydroxyalkyl and R 4 is -(Cl-C6)aikyi.
- R 3 is ⁇ 0(C1-C6)alkyl which is optionally substituted with OH or (Cl-C4)aikoxy
- R 4 is hydrogen
- R 5 include -OMe, -OEt, -OCH 2 CH 2 OH, -OCH 2 CH 2 CH 2 OH, -OCH 2 CH(OH)CH 3 , -OCI I ( ' (( ' i I-, j ⁇ I. -OCI I CS X ' i !-,. OCH 2 CH 2 CH 2 OCH 3 , and -OCH 2 CH(OCH 3 )CH 3 .
- R " is:
- NR 4 R 5 forms a 4-7 membered heterocyclic ring having a ring nitrogen atom and optionally having a second ring heteroatom selected from N and O, wherein said ring is optionally substituted with one or more substituents independently selected from (CI-C6)alkyl, OH, COOH, and (C1-C3 alkyl)COOH.
- the heterocyclic ring is optionally substituted with one or two of said substituents. Particular examples include, but are not limited to, the following structures:
- R 1 is phenyl optionally substituted with one or more substituents independently seiected from halogen, (Cl.-C4)alkoxy, -CF 3 , -CHF 2 , -0(C1 -C4 alkyl), -(Cl-C4)alkyl and NH 2 , or a 5-6 membered heteroaryl ring having a ring heteroatom selected form N and S, wherein said heteroaryl ring is optionally substituted with one or more substituents independently selected from halogen, -0(C1-C4 alkyl), (Cl -C4)alkyl and NH 2 , or a pyrid-2-on-3-yl ring optionally substituted with one or more substituents independently selected from halogen and (Cl-C4)alkyl.
- Particular examples include, but are not limited to, the following structures;
- the compounds disclosed herein may exist as individual enantiomers and diastereomers or as mixtures of such isomers, including racemates. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included in the scope of the compounds disclosed herein. Furthermore, compounds disclosed herein may exist in one or more crystalline or amorphous forms. Unless otherwise indicated, all such forms are included in the scope of the compounds disclosed herein including any polymorphic forms. In addition, some of the compounds disclosed herein may form solvates with water (i.e., hydrates) or common organic solvents. Unless otherwise indicated, such solvates are included in the scope of the compounds disclosed herein.
- Isotopes may be present in the compounds described. Each chemical element as represented in a compound structure may include any isotope of said element.
- a hydrogen atom may be explicitly disclosed or understood to be present in the compound.
- the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen- 1 (protium) and hydrogen-2 (deuterium).
- reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
- novel compounds disclosed above are inhibitors of TrkA, TrkB and/or TrkC and are useful for treating pain, cancers and other hyperproliferative diseasesln one aspect, the present invention provides a pharmaceutical composition including one or more of the chemical compounds of Formula I or their pharmaceutically acceptable salts, solvates, polymorphs, esters, tautomers or prodrugs for use in treating painm cancers and other hyperproliferative diseases.
- the pharmaceutical composition includes an effective amount of a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. Further, the pharmaceutical composition further includes a pharmaceutically acceptable carrier, adjuvants and/or excipients. In some embodiments, such a composition may contain at least one of preservatives, agents for delaying absorption, fillers, binders, adsorbents, buffers, disintegrating agents, solubilizing agents, and other carriers, adjuvants and/or excipients as inert ingredients.
- the composition may be Formulated with a method well-known in the art.
- the pharmaceutical composition is in a form suitable for oral administration.
- the pharmaceutical composition is in the form of a tablet, capsule, pill, powder, sustained release Formulation, solution and suspension.
- the pharmaceutical composition is in a form suitable for parenteral injection, such as a sterile solution, suspension or emulsion; for topical administration as an ointment or cream or for rectal administration as a suppository.
- the composition comprising a compound of Formula I is administered orally, intraduodenally, parenterally (including intravenous, subcutaneous, intramuscular, intravascular or by infusion), topically or rectally.
- the pharmaceutical composition is in a form suitable for oral administration.
- the pharmaceutical composition is in the form of a tablet, capsule, pill, powder, sustained release Formulations, solution and suspension for oral administration, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream, or for rectal administration as a suppository.
- the pharmaceutical composition is in unit dosage forms suitable for single administration of precise dosages.
- the pharmaceutical composition further comprises a pharmaceutical carrier, excipient and' r adjuvant.
- the present invention provides a method of admimnstering a therapeutically effective amount of the pharmaceutical composition to a subject for the treatment of pain, inflammation, neurodegenerative diseases, certain infectious diseases, cancer, other hyperproliferative diseases or conditions modulated by the Trk cascade in a mammal including human.
- the present invention provides a method for inhibiting a Trk enzyme.
- the method comprises contacting said Trk enzyme with an amount of a composition comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, sufficient to inhibit said enzyme, wherein said enzyme is inhibited.
- the present invention is directed to a method for selectively inhibiting a Trk enzyme.
- the present invention is directed to use of a compound of Formula I or a phannaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for inhibiting a Trk enzyme.
- the Trk enzyme is Trk kinase. In some embodiments the Trk enzyme is TrkA. In some embodiments the Trk enzyme is TrkB. In some embodiments, the Trk enzyme is TrkC.
- the compounds of Formula I can selecti vely inhibit a TrkA enzyme, TrkB enzyme or TrkC enzyme. In some other embodiments, the compounds of Formula I may not have a selectivity from TrkA enzyme, TrkB enzyme and TrkC enzyme.
- the contacting occurs within a cell.
- the cell is a mammalian cell.
- the mammalian cell is a human cell.
- the Trk enzyme is inhibited with a composition comprising a pharmaceutically acceptable salt of a compound of Formula I.
- the present invention is directed to a method of treatment of a Trk mediated disorder in an individual suffering from said disorder comprising administering to said individual an effective amount of a composition comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.
- the present invention is directed to use of a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for treating a Trk mediated disorder.
- the pharmaceutical composition is in unit dosage forms suitable for single administration of precise dosages.
- the amount of compound of Formula I is in the range of about 0.001 to about 1000 mg/kg body weight/day. In further or additional embodiments, the amount of compound of Formula I is in the range of about 0.5 to about 50 mgkg body weight/day. In further or additional embodiments the amount of compound of Formula I is about 0.001 to about 7 g/day. In furtlier or additional embodiments the amount of compound of Formula I is about 0.002 to about 6 g'day. In fmlher or additional embodiments the amount of compound of Formula I is about 0.005 to about 5 g/day.
- the amount of compound of Formula I is about 0.01 to about 5 g day. In further or additional embodiments the amount of compound of Formula I is about 0.02 to about 5 g day. In furtlier or additional embodiments the amount of compound of Formula I is about 0.05 to about 2.5 g/day. In furtlier or additional embodiments the amount of compound of Formula I is about 0.1 to about 1 g/day.
- dosage levels below the lower limit of the aforesaid range may be more than adequate. In fuilher or additional embodiments, dosage levels above the upper limit of the aforesaid range may be required.
- the compound of Formula I is administered in a single dose, once daily. In further or additional embodiments the compound of Formula I is administered in multiple doses, more than once per day. In further or additional embodiments the compound of Formula I is administered twice daily. In further or additional embodiments the compound of Formula I is administered three times per day. In further or additional embodiments the compound of Formula I is administered four times per day. In further or additional embodiments the compound of Formula I is administered more than four times per day. In some embodiments, the pharmaceutical composition is for administration to a mammal.
- the pharmaceutical composition further comprises at least one therapeutic agent.
- the therapeutic agent is selected from the group consisting of cytotoxic agen ts, anti-angiogenesis agen ts and anti-neoplastic agents.
- the anti-neoplastic agent is selected from the group consisting of alkylating agents, anti-metabolites, epidophyllotoxins; antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, hormonal''anti-hormonal therapeutic agents, and haematopoietic growth factors.
- the therapeutic agent is taxol, bortezomib or both.
- the pharmaceutical composition is administered in combination with an additional therapy.
- the additional therapy is radiation therapy, chemotherapy or a combination of both.
- the pharmaceutical composition comprises a pharmaceutically acceptable salt of a compound of Formula I.
- the enzyme is at least about 1% inhibited. In further or additional embodiments the enzyme is at least about 2% inhibited. In further or additional embodiments the enzyme is at least about 3% inhibited In further or additional embodiments the enzyme is at least about 4% inhibited. In further or additional embodiments the enzyme is at least about 5% inhibited. In furtlier or additional embodiments the enzyme is at least about 10% inhibited. In furtlier or additional embodiments the enzyme is at least about 20% inhibited. In furtlier or additional embodiments the enzyme is at least about 25% inhibited. In further or additional embodiments the enzyme is at least about 30% inhibited. In further or additional embodiments the enzyme is at least about 40% inhibited.
- the enzyme is at least about 50% inhibited. In further or additional embodiments the enzyme is at least about 60% inhibited. In further or additional embodiments the enzyme is at least about 70% inhibited. In further or additional embodiments the enzyme is at least about 75% inhibited. In further or additional embodiments the enzyme is at least about 80% inhibited. In further or additional embodiments the enzyme is at least about 90% inhibited. In further or additional embodiments the enzyme is essentially completely inhibited.
- the amount of compound of Formula I is in the range of about 0.001 to about 1000 nig/kg body weight-'day. In further or additional embodiments the amount of compound of Formula I is in the range of about 0.5 to about 50 mg/kg body weight day. In further or additional embodiments the amount of compound of Formula I is about 0.001 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.01 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.02 to about 5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.05 to about 2.5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.1 to about 1 g/day.
- dosage levels below the lower limit of the aforesaid range may be more than adequate. In furtlier or additional embodiments, dosage levels above the upper limit of the aforesaid range may be required.
- the compound of Formula I is administered in a single dose, once daily. In further or additional embodiments the compound of Formula I is administered in multiple doses, more than once per day. In furtlier or additional embodiments the compound of Formula I is administered twice daily. In further or additional embodiments the compound of Formula I is administered three times per day. In further or additional embodiments the compound of Formula I is administered four times per day. In further or additional embodiments the compound of Formula I is administered more than four times per day.
- the individual suffering from the Trk mediated disorder is a mammal. In further or additional embodiments, the individual is a human. In some embodiments, the composition comprising a compound of Formula I is administered in combination with an additional therapy. In further or additional embodiments, the additional therapy is radiation therapy, chemotherapy or a combination of both. In further or additional embodiments, the composition comprising a compound of Formula I is administered in combination w th at least one therapeutic agent. In further or additional embodiments, the therapeutic agent is selected from the group of cytotoxic agents, anti-angiogenesis agents and antineoplastic agents.
- the anti-neoplastic agent is selected from the group of consisting of alkylating agents, anti-metabolites, epidophyllotoxms; antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, hormonal/anti-hormonal therapeutic agents, and haematopoietic growth factors.
- the therapeutic agent is selected from taxol, bortezomib or both.
- the Trk mediated disorder is selected from the group consisting of inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorder, neurological disorders, fibrogenic disorders, proliferative disorders, hype ⁇ oliferative disorders, non- cancer hyper- proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, malignant disease, vascular restenosis, psoriasis, atherosclerosis, rheumatoid arthritis, osteoarthritis, heart failure, chronic pain, neuropathic pain, dry eye, closed angle glaucoma and wide angle glaucoma.
- the Trk mediated disorder is an inflammatory disease. In further or additional embodiments, the Trk mediated disorder is a hypeqDroliferative disease. In further or additional embodiments, the Trk mediated disorder is selected from the group consisting of tumors, leukemias, neoplasms, cancers, carcinomas and malignant disease. In further or additional embodiments, the cancer is brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, colorectal cancer or leukemia.
- the fibrogenetic disorder is scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis or pulmonary fibrosis.
- an effective amount of a composition comprising a pharmaceutically acceptable salt of a compound of Formula I is administered.
- the present invention is directed to a method for degrading, inhibiting the growth of or killing a cancer cell comprising contacting said cell with an amount of a composition effective to degrade, inhibit the gro wth of or to kill said cell, the composition comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.
- the present invention is directed to use of a compound of Formula I or a pharmaceutically acceptable salt solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for degrading and/or inhibiting the growth of or killing a cancer cell.
- the cancer cells comprise brain, breast lung, ovarian, pancreatic, prostate, renal, or colorectal cancer cells.
- the composition is administered with at least one therapeutic agent.
- the therapeutic agent is taxol, bortezomib or both.
- the therapeutic agent is selected from the group consisting of cytotoxic agents, anti-angiogenesis agents and anti-neoplastic agents.
- the anti-neoplastic agents selected from the group of consisting of alkylating agents, anti-metabolites, epidophyllotoxins; antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, horrnonal/anti-hormonal therapeutic agents, and haematopoietic growth factors.
- the cancer cells are degraded. In further or additional embodiments, 1% of the cancer cells are degraded. In further or additional embodiments, 2% of the cancer cells are degraded. In further or additional embodiments, 3% of the cancer cells are degraded. In further or additional embodiments, 4% of the cancer cells are degraded. In further or additional embodiments, 5% of the cancer cells are degraded. In further or additional embodiments, 10% of the cancer cells are degraded. In further or additional embodiments, 20% of the cancer cells are degraded. In further or additional embodiments, 25% of the cancer cells are degraded. In further or additional embodiments, 30% of the cancer cells are degraded. In further or additional embodiments, 40% of the cancer cells are degraded.
- 50% of the cancer cells are degraded.
- 60% of the cancer cells are degraded.
- 70% of the cancer cells are degraded.
- 75% of the cancer cells are degraded.
- 80% of the cancer cells are degraded.
- 90% of the cancer cells are degraded.
- 100% of the cancer cells are degraded.
- essentially all of the cancer ceils are degraded.
- the cancer cells are killed. In former or additional embodiments, 1% of the cancer cells are killed. In further or additional embodiments, 2% of the cancer ceils are killed. In further or additional embodiments, 3% of the cancer cells are killed. In further or additional embodiments, 4% of the cancer cells are killed. In further or additional embodiments, 5% of the cancer cells are killed. In further or additional embodiments, 10% of the cancer ceils are killed. In further or additional embodiments, 20% of the cancer cells are killed. In further or additional embodiments, 25% of the cancer ceils are killed. In further or additional embodiments, 30% of the cancer ceils are killed. In further or additional embodiments, 40% of the cancer cells are killed. In further or additional embodiments, 50% of the cancer cells are killed.
- 60% of the cancer cells are killed.
- 70% of the cancer cells are killed.
- 75% of the cancer cells are killed.
- 80% of the cancer cells are killed.
- 90% of the cancer cells are killed.
- 100% of the cancer cells are killed.
- essentially all of the cancer cells are killed.
- the growth of the cancer cells is inhibited. In further or additional embodiments, the growth of the cancer cells is about 1% inhibited. In further or additional embodiments, the growth of the cancer cells is about 2% inhibited, in further or additional embodiments, the growth of the cancer cells is about 3% inhibited, in further or additional embodiments, the growth of the cancer cells is about 4% inhibited. In further or additional embodiments, the growth of the cancer ceils is about 5% inhibited. In further or additional embodiments, the growth of the cancer cells is about 10% inhibited. In further or additional embodiments, the growth of the cancer cells is about 20% inhibited. In further or additional embodiments, the growth of the cancer cells is about 25% inhibited.
- the growth of the cancer cells is about 30% inhibited. In further or additional embodiments, the growth of the cancer ceils is about 40% inhibited. In further or additional embodiments, the growth of the cancer ceils is about 50"% inhibited. In further or additional embodiments, the growth of the cancer ceils is about 60% inhibited. In further or additional embodiments, the growth of the cancer ceils is about 70% inhibited. In further or additional embodiments, the growth of the cancer cells is about 75% inhibited. In further or additional embodiments, the growth of the cancer cells is about 80% inhibited. In further or additional embodiments, the growth of the cancer cells is about 90% inhibited. In further or additional embodiments, the growth of the cancer cells is about 100% inhibited. In further or additional embodiments, a composition comprising a pharmaceutically acceptable salt of a compound of Formula I is used.
- the present invention is directed to a method for the treatment or prophylaxis of a proliferative disease in an individual comprising administering to said individual an effective amount of a composition comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or pro-drug thereof.
- the present invention is directed to use of a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for the treatment or prophylaxis of a proliferative disease.
- the proliferative disease is cancer, psoriasis, restenosis, autoimmune disease, or atherosclerosis. In further or additional embodiments, the proliferative disease is a hyperproliferative disease. In further or additional embodiments, the proliferative disease is selected from the group consisting of tumors, leukemias, neoplasms, cancers, carcinomas and malignant disease. In further or additional embodiments, the cancer is brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, colorectal cancer or leukemia.
- the fibrogenetic disorder is scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis or pulmonary fibrosis.
- the cancer is brain cancer, breast cancer, lung cancer, ovanan cancer, pancreatic cancer, prostate cancer, renal cancer, colorectal cancer or leukemia.
- the cancer is brain cancer or adrenocortical carcinoma.
- the cancer is breast cancer.
- the cancer is ovarian cancer.
- the cancer is pancreatic cancer.
- the cancer is prostate cancer. In further or additional embodiments, the cancer is renal cancer. In further or additional embodiments, the cancer is colorectal cancer. In further or additional embodiments, the cancer is myeloid leukemia. In further or additional embodiments, the cancer is glioblastoma. In further or additional embodiments, the cancer is follicular lymphoma. In further or additional embodiments, the cancer is pre-B acute leukemia. In further or additional embodiments, the cancer is chronic lymphocytic B-leukemia. In further or additional embodiments, the cancer is mesothelioma. In further or additional embodiments, the cancer is small cell line cancer.
- the composition comprising a compound of Formula I is administered in combination with an additional therapy.
- the additional therapy is radiation therapy, chemotherapy or a combination of both.
- the composition comprising a compound of Formula I is administered in combination with at least one therapeutic agent.
- the therapeutic agent is selected from the group of cytotoxic agents, anti-angiogenesis agents and antineoplastic agents.
- the anti-neoplastic agent is selected from the group of consisting of alkylating agents, anti-metabolites, epidophyilotoxins; antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, hormonal/anti-hormonal therapeutic agents, and haematopoietic growth factors.
- the therapeutic agent is selected from taxol, bortezomib or both.
- the composition is administered orally, intraduodenally, parenterally (including intravenous, subcutaneous, intramuscular, intravascular or by infusion), topically or rectally.
- the amount of compound of Formula I is in the range of about 0.001 to about 1000 mg/kg body weight/day. In further or additional embodiments the amount of compound of Formula I is in the range of about 0.5 to about 50 mg/kg body weight /day. In further or additional embodiments the amount of compound of Formula I is about 0.001 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.01 to about 7 g/day. in further or additional embodiments the amount of compound of Formula I is about 0.02 to about 5 g'day. In further or additional embodiments the amount of compound of Formula I is about 0.05 to about 2.5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.1 to about 1 g/day. In further or additional embodiments, dosage levels below the lower limit of the aforesaid range may be more than adequate. In further or additional embodiments, dosage levels above the upper limit of the aforesaid range may be required.
- the compound of Formula I is administered in a single dose, once daily. In further or additional embodiments the compound of Formula I is administered in multiple doses, more than once per day. In further or additional embodiments the compound of Formula I is administered twice daily. In further or additional embodiments the compound of Formula I is administered three times per day. In further or additional embodiments the compound of Formula I is administered four times per day. In further or additional embodiments the compound of Formula I is administered more than four times per day.
- the individual suffering from the proliferative disease is a mammal. In further or additional embodiments, the individual is a human. In further or additional embodiments, an effective amount of a composition comprising a pharmaceutically acceptable salt of a compound of Formula I is administered.
- the present invention is directed to a method for the treatment or prophylaxis of an inflammatory disease in an individual comprising administering to said individual an effective amount of a composition comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.
- the present invention is directed to use of a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for the treatment or prophylaxis of an inflammatory disease.
- the inflammatory disease is selected from chronic inflammatory diseases, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, juvenile arthritis, acute rheumatic arthritis, enteropathic arthritis, neuropathic arthritis, psoriatic arthritis, pyogenic arthritis, atherosclerosis, systemic lupus erythematosus, inflammatory bowel disease, irritable bowel syndrome, ulcerative colitis, reflux esophagitis, Crohn's disease, gastritis, asthma, allergies, respiratory distress syndrome, pancreatitis, chronic obstructive pulmonary disease, pulmonary fibrosis, psoriasis, eczema or scleroderma.
- chronic inflammatory diseases rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, juvenile arthritis, acute rheumatic arthritis, enteropathic arthritis, neuropathic arthritis, psoriatic arthritis,
- the composition comprising a compound of Formula is administered in combination with an additional therapy. In further or additional embodiments, the composition comprising a compound of Formula is administered in combination with at least one therapeutic agent. In some embodiments, the composition is administered orally, intraduodenally, parenteral! ⁇ ' (including intravenous, subcutaneous, intramuscular, intravascular or by infusion), topically or rectally.
- the amount of compound of Formula I is in the range of about 0.001 to about 1000 mg/kg body weight day. In further or additional embodiments the amount of compound of Formula I is in the range of about 0.5 to about 50 mgkg body weight /day. In further or additional embodiments the amount of compound of Formula I is about 0.001 to about 7 g/'day. In further or additional embodiments the amount of compound of Formula I is about 0.01 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.02 to about 5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.05 to about 2.5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.1 to about 1 g/day. In further or additional embodiments, dosage levels below the lower limit of the aforesaid range may be more than adequate. In further or additional embodiments, dosage levels above the upper limit of the aforesaid range may be required.
- the compound of Formula I is administered in a single dose, once daily. In further or additional embodiments the compound of Formula I is administered in multiple doses, more than once per day. In further or additional embodiments the compound of Formula I is administered twice daily. In further or additional embodiments the compound of Formula I is administered three times per day. In further or additional embodiments the compound of Formula I is administered four times per day. In further or additional embodiments the compound of Formula I is administered more than four times per day.
- the individual suffering from the inflammatory disease is a mammal. In further or additional embodiments, the individual is a human. In further or additional embodiments, an effective amount of a composition comprising a pharmaceutically acceptable salt of a compound of Formula I is administered.
- the present invention is directed to a method for the treatment or prophylaxis of cancer in an individual comprising administering to said individual an effective amount of a composition comprising a compound of Formula I or a pharmaceutically acceptable salt solvate, polymorph, ester, tautomer or prodrug thereof.
- the present invention is directed to use of a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for the treatment or prophylaxis of a cancer.
- the cancer is brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, colorectal cancer or leukemia.
- the fibrogenetic disorder is scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis or pulmonary fibrosis.
- the cancer is brain cancer, breast cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, colorectal cancer or leukemia.
- the cancer is brain cancer or adrenocortical carcinoma.
- the cancer is breast cancer. In further or additional embodiments, the cancer is ovarian cancer. In further or additional embodiments, the cancer is pancreatic cancer. In further or additional embodiments, the cancer is prostate cancer. In further or additional embodiments, the cancer is renal cancer. In further or additional embodiments, the cancer is colorectal cancer. In further or additional embodiments, the cancer is myeloid leukemia. In further or additional embodiments, the cancer is glioblastoma. In further or additional embodiments, the cancer is follicular lymphoma. In further or additional embodiments, the cancer is pre-B acute leukemia. In further or additional embodiments, the cancer is chronic lymphocytic B-leukemia. In further or additional embodiments, the cancer is mesothelioma. In further or additional embodiments, the cancer is small cell line cancer.
- the composition comprising a compound of Formula I is administered in combination with an additional therapy.
- the additional therapy is radiation therapy, chemotherapy or a combination of both.
- the composition comprising a compound of Formula I is administered in combination with at least one therapeutic agent.
- the therapeutic agent is selected from the group of cytotoxic agents, anti-angiogenesis agents and anti-neoplastic agents.
- the anti-neoplastic agent is selected from the group of consisting of alkylating agents, anti-metabolites, epidophyllotoxins; antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, hormonal/anti-hormonal therapeutic agents, and haematopoietic growth factors.
- the therapeutic agent is selected from taxol, bortezormb or both.
- the composition is administered orally, intraduodenally, parenterally (including intravenous, subcutaneous, intramuscular, intravascular or by infusion), topically or rectally.
- the amount of compound of Formula I is in the range of about 0.001 to about 1000 mg/kg body weight day. In further or additional embodiments the amount of compound of Formula I is in the range of about 0.5 to about 50 mg/kg body weight /day. In further or additional embodiments the amount of compound of Formula I is about 0.001 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.01 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.02 to about 5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.05 to about 2.5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.1 to about 1 g day. In further or additional embodiments, dosage levels below the lower limit of the aforesaid range may be more than adequate. In further or additional embodiments, dosage levels above the upper limit of the aforesaid range may be required.
- the compound of Formula I is administered in a single dose, once daily. In furtlier or additional embodiments the compound of Formula I is administered in multiple doses, more than once per day. In further or additional embodiments the compound of Formula I is administered twice daily. In further or additional embodiments the compound of Formula I is administered three times per day In further or additional embodiments the compound of Formula I is administered four times per day. In furtlier or additional embodiments the compound of Formula I is administered more than four times per day. In some embodiments, the individual suffering from cancer is a mammal. In further or additional embodiments, the individual is a human. In further or additional embodiments, an effective amount of a composition comprising a pharmaceutically acceptable salt of a compound of Formula I is administered.
- the present invention is directed to a method of reducing the size of a tumor, inhibiting tumor size increase, reducing tumor proliferation or preventing tumor proliferation in an individual, comprising administering to said individual an effective amount of a composition comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.
- the present invention is directed to use of a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for reducing the size of a tumor, inhibiting tumor size increase, reducing tumor proliferation or preventing tumor proliferation.
- the size of a tumor is reduced. In further or additional embodiments, the size of a tumor is reduced by at least 1%. In further or additional embodiments, the size of a tumor is reduced by at least 2%. In further or additional embodiments, the size of a tumor is reduced by at least 3%. In furtlier or additional embodiments, the size of a tumor is reduced by at least 4%. In furtlier or additional embodiments, the size of a tumor is reduced by at least 5%. In further or additional embodiments, the size of a tumor is reduced by at least 10%. In further or additional embodiments, the size of a tumor is reduced by at least 20%. In further or additional embodiments, the size of a tumor is reduced by at least 25%.
- the size of a tumor is reduced by at least 30%. In further or additional embodiments, the size of a tumor is reduced by at least 40%. In further or additional embodiments, the size of a tumor is reduced by at least 50%. In further or additional embodiments, the size of a tumor is reduced by at least 60%. In further or additional embodiments, the size of a tumor is reduced by at least 70%. In further or additional embodiments, the size of a tumor is reduced by at least 75%. In further or additional embodiments, the size of a tumor is reduced by at least 80%. In further or additional embodiments, the size of a tumor is reduced by at least 85%. In further or additional embodiments, the size of a tumor is reduced by at least 90%. In further or additional embodiments, the size of a tumor is reduced by at least 95%. In further or additional embodiments, the tumor is eradicated. In some embodiments, the size of a tumor does not increase.
- tumor proliferation is reduced. In some embodiments, tumor proliferation is reduced by at least 1%. In some embodiments, tumor proliferation is reduced by at least 2%. In some embodiments, tumor proliferation is reduced by at least 3%. In some embodiments, tumor proliferation is reduced by at least 4%. In some embodiments, tumor proliferation is reduced by at least 5%. In some embodiments, tumor proliferation is reduced by at least 0%. In some embodiments, tumor proliferation is reduced by at least 20%. In some embodiments, tumor proliferation is reduced by at least 25%. In some embodiments, rumor proliferation is reduced by at least 30%. In some embodiments, tumor proliferation is reduced by at least 40%. In some embodiments, tumor proliferation is reduced by at least 50%. In some embodiments, tumor proliferation is reduced by at least 60%.
- tumor proliferation is reduced by at least 70%. In some embodiments, tumor proliferation is reduced by at least 75%. in some embodiments, tumor proliferation is reduced by at least 80%. In some embodiments, tumor proliferation is reduced by at least 90%. In some embodiments, tumor proliferation is reduced by at least 95%. In some embodiments, tumor proliferation is prevented.
- the composition comprising a compound of Formula I is administered in combination with an additional therapy.
- the additional therapy is radiation therapy, chemotherapy or a combination of both.
- the composition comprising a compound of Formula I is administered in combination with at least one therapeutic agent.
- the therapeutic agent is selected from the group of cytotoxic agents, anti-angiogenesis agents and antineoplastic agents.
- the antineoplastic agent is selected from the group of consisting of alkylating agents, anti-metabolites, epidophyllotoxins; antineoplastic enzy mes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inliibitors, hormonal''anti4 onnonal therapeutic agents, and haematopoietic growth factors.
- the therapeutic agent is selected from taxol, bortezomib or both.
- the composition is administered orally, intraduodenally, parenterally (including intravenous, subcutaneous, intramuscular, intravascular or by infusion), topically or rectally.
- the amount of compound of Formula I is in the range of about 0.001 to about 1000 mg kg body weight'day. In further or additional embodiments the amount of compound of Formula I is in the range of about 0.5 to about 50 mg/kg body weight/day. In further or additional embodiments the amount of compound of Formula I is about 0.001 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.01 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.02 to about 5 g day. In further or additional embodiments the amount of compound of Formula I is about 0.05 to about 2.5 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.1 to about 1 g/day. In further or additional embodiments, dosage levels below the lower limit of the aforesaid range may be more than adequate. In further or additional embodiments, dosage levels above the upper limit of the aforesaid range may be required.
- the compound of Formula I is administered in a single dose, once daily. In further or additional embodiments the compound of Formula I is administered in multiple doses, more than once per day. In further or additional embodiments the compound of Formula I is administered twice daily. In further or additional embodiments the compound of Formula I is administered three times per day. In further or additional embodiments the compound of Formula I is administered four times per day. In further or additional embodiments the compound of Formula I is administered more than four times per day.
- the individual suffering from cancer is a mammal. In further or additional embodiments, the individual is a human. In further or additional embodiments, an effective amount of a composition comprising a pharmaceutically acceptable salt of a compound of Formula I is administered.
- the present invention is directed to a method for achieving an effect in a patient comprising the administration of an effective amount of a composition comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, to a patient, wherein the effect is selected from the group consisting of inhibition of various cancers, immunological diseases, and inflammatory diseases.
- the effect is inhibition of various cancers.
- the effect is inhibition of immunological diseases.
- the effect is inhibition inflammatory diseases.
- the present invention is directed to use of a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof in the preparation of a pharmaceutical composition for the inhibiting various cancers, immunological diseases, and/or inflammatory diseases.
- the composition comprising a compound of Formula I is administered in combination with an additional therapy.
- the additional therapy is radiation therapy, chemotherapy or a combination of both.
- the composition comprising a compound of Formula I is administered in combination with at least one therapeutic agent.
- the composition is administered orally, intraduodenally, parenterally (including intravenous, subcutaneous, intramuscular, intravascular or by infusion), topically or rectally.
- the amount of compound of Formula I is in the range of about 0.001 to about 1000 mg kg body weight/day. In further or additional embodiments the amount of compound of Formula I is in the range of about 0.5 to about 50 mg kg body weight /day. In further or additional embodiments the amount of compound of Formula I is about 0.001 to about 7 g day. In further or additional embodiments the amount of compound of Formula I is about 0.01 to about 7 g/day. In further or additional embodiments the amount of compound of Formula I is about 0.02 to about 5 g/day. In turther or additional embodiments the amount of compound of Formula I is about 0.05 to about 2.5 g-'day.
- the amount of compound of Formula I is about 0.1 to about 1 g/day. In further or additional embodiments, dosage levels below the lower limit of the aforesaid range may be more than adequate. In further or additional embodiments, dosage levels above the upper limit of the aforesaid range may be required.
- the compound of Formula I is administered in a single dose, once daily. In further or additional embodiments the compound of Formula I is administered in multiple doses, more than once per day. In further or additional embodiments the compound of Formula I is administered twice daily. In further or additional embodiments the compound of Formula I is administered three times per day. In further or additional embodiments the compound of Formula I is administered four times per day. In further or additional embodiments the compound of Formula I is administered more than four times per day.
- the individual suffering from cancer is a mammal. In further or additional embodiments, the individual is a human.
- an effective amount of a composition comprising a pharmaceutically acceptable salt of a compound of Formula I is administered. In some embodiments, the present invention is directed to a process for preparing a compound of Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof.
- the foregoing scheme provides general synthetic routes for the compounds of Formula I, II, and IV.
- the key intermediate compound 3 can be obtained via coupling reaction of cyclic amine compounds with the bicyclic hetero cyclic compound 1 containing various functional groups Q.
- the various five membered heterocyclic moieties in the compounds of Formula I are introduced via coupling reaction, condensation, or cyclization reactions from the compound 3.
- the compounds of Formula II can be prepared from the compound 3 containing aldehyde moiety through HEW reaction, hydrolysis followed by amide coupling reaction.
- Sonogashira reaction with iodo compound 3 afforded the desired compounds.
- NMR spectra were recorded i CDCI 3 and OMSO-d ⁇ solution in 5-mm o.d.
- Step B tert-butyl 4-(5-fluoropyridin-3-yl)-4-oxobutylcarbamate
- Step C 3-(3,4-dihydro-2H-pyrrol-5-y -5-fluoropyridine
- Step A tert-butyl 4-(2,5-difluorophenyl)-4-oxobutylcarbamate
- Step A 2-(but-3-ynyl)isoindoline-l,3-dione
- Step B 2-(4-(5-fluoro-2-methoxypyridin-3-yl)but-3-ynyl)isoindoline- 1 ,3-dione
- Step D 3-(3,4-dihydro-2H-pyrrol-5-y -5-fluoro-2-methoxypyridine
- Step B 4-chloro- 1 -(5-fluoropyridin-3-yl)butan- 1 -one
- Step C (S,Z)-N-(4-chloro-l-(5-fluoropyridin-3-yl)butylidene)-2-methylpropane-2-sulfin- amide.
- Step D 3-((R)-l-((S)-tert-butylsulfinyl)-pyrrolidin-2-yl)-5-fluoropyridine
- Step A 4-chloro-l -(2,5-difluorophenyl)butan-l -one
- Step B (S,Z)-N-(4-chloro-l-(2,5-difluorophenyl)butylidene)-2-methylpropane-2- sulfinamide
- Step C (R)-l -((S)-tert-butylsulfinyl -2-(2,5-difluorophenyl)pyrrolidine
- Step B (R)-tert-butyl 4-(tert-butyldimethylsilyloxy)-2-oxopyrrolidine-l-carboxylate
- Step D (4R)-tert-butyl 4-(tert-butyldimethylsilyloxy)-2-(2,5-difluorophenyl)pyrrolidine- 1-carboxylate
- Step E (4R)-tert-butyl 2-(2,5-difluorophenyl)-4-hydroxypyrrolidine-l-carboxylate
- Step F (2R,4S)-tert-butyl 2-(2,5-difluorophenyl)-4-fluoropyrrolidine-l -carboxylate (6a) and (2S,4S)-tert-butyl 2-(2,5-difluorophenyl)-4-fluoropyrrolidine-l -carboxylate (7a)
- TToo aa ssoolluuttiioonn ooff ((22SS,,44SS))--tteerrtt--bbuuttyyll 22--((22,,55--ddiifflluuoorroopphheennyyll))--44--fflluuoorrooppyyrrrroolliiddiinnee--ll-- ccaarrbbooxxyyllaattee ((225522 mmgg,, 00..883366 mmmmooll)) iinn DDCCMM ((11..6677 mmLL)) wwaass aaddddeedd TTFFAA ( (11..2299 m mLL,, 1166..77 mmmmooll)) aatt rroooomm tteemmppeerraattuurree..
- Step B ethyl 5-chloropyrazolo[l,5-a]pyrimidine-3-carbox late
- Step C ethyl 5-(2-(2,5-difluorophenyl)pyrrolidin-l -yi)pyrazolo[ 1 ,5-a]pynmidme-3 carboxylate
- Step I 5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidine-3-carboxylic
- Step A ethyl 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l -yl)pyrazolo[ 1 ,5-a]pyrimidine-3- carboxylate
- Step B 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidine- carboxylic acid
- Step A N'-acetyl-5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidine-3- carbohydrazide
- Step B 2-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3-yl)-5- methyl- 1 ,3,4-oxadiazole.
- Step A tert-butyl 2-propionylhydrazinecarboxylate
- Step D 2-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3-yl)-5- ethyl- 1 , 3 ,4-oxadiazole
- Step A tert-butyl 2-isobutyrylhydrazinecarboxylate
- Step B isobut rohydrazide hydrochloride
- Step C 5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)-N'-isobutyrylpyrazolo[l ,5- a]pyrimidine-3-carbohydrazide
- Step D 2-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3-yl)-5- isopropyl-l,3,4-oxadiazole.
- Example 14 Preparation of Chemical Compound 6; 2-(5-(2- 2,5- ⁇ 6 ⁇ ⁇ 1) ⁇ 1- ⁇ - l-yDpyrazoioI ' l ⁇ -alpyrimidin-S-yD-S-isopropyi-l ⁇ -thiadiazole
- the reaction mixture was stirred aatt 111100 °°CC ffoorr 22 hhoouurrss,, ccoooolleedd ttoo rroooomm tteemmppeerraattuurree aanndd pplortitittiioonneedd bbeettwweeeenn wwaatteerr aanndd EEttOOAAcc..
- Step A tert-butyl 2-(cyclopropanecarbonyl)hydrazinecarboxylate
- Step B cyclopropanecarbohydrazide hydrochloride
- Step C N'-(cyclopropanecarbonyl)-5-(2-(2,5-difluorophenyl)pyrrolidin-l - yl)pyrazolo[l,5-a]pyrimidine-3-carbohydrazide.
- Step A tert-butyl 2-pivaloylhydrazinecarboxylate
- Step D 2-tert-butyl-5-(5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolo[l,5- a]pyrimidin-3 ⁇ yl) ⁇ 1 , 3 ,4-oxadiazole
- Step A N'-acetyl-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l -yl)pyrazolo[l,5-a]pyrimidine- 3 -carbohy drazi de
- Step B 2-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l ,5-a]pyrimidin-3-yl)-5- methyl- 1 ,3,4-thiadiazole
- Step A N'-acetyl-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l ,5-a]pyrimidine- 3-carbohydrazide
- Step B 2-eihyl-5-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrirnidin-
- Step A 5-(2-(5-fluoropyridin-3-yl)pyrrolidin- 1 -yl)-N'-isobutyrylpyrazolo[l ,
- Step B 2-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrirnidin-3-yl)-5- isopropyl- 1 ,3,4-thiadiazofe
- Step A N'-(cyclopropanecarbonyl)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l- yl)pyrazolo[l,5-a]pyrimidine-3-carboh razide
- Step B 2-cyclopropyl-5-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l,5- a]pyrimidin-3 -yl)- 1 , 3 ,4-thiadiazole
- Step B 2-tert-butyl-5-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l -yl)pyrazolo[ 1,5- a]pyrimidin-3-yl)-l,3,4-thiadiazole
- Step A Ethyl (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolo[l ,5-a]pyrimidine earboxylate
- Step B (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-l -yi)pyrazolo[l ,5-a]pyrimidine-3- carboxylic acid
- Step A (R)-ethyl 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l ,5-a]pyrimidine- 3-carboxylate
- Step B (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l -yl)pyrazolo[ 1 ,5-a]pyrimidine-3- car boxy lie acid
- TToo aa ssoolluuttiioonn ooff ((RR))--eetthhyyll 55--((22--((55--fflluuoorrooppyyririddiinn--33--yyll))ppyyrrrroolliiddiinn--ll --yyll))ppyyrraazzoollooff ll,,55-- aa]]ppyyrriimmiiddiinnee--33--ccaarrbbooxxyyllaattee ((66..5566 gg,, 188..44 mmmmooll)) iinn EEttOOHH ((7700 m mLL)) aanndd wwaatteerr ((2233 m mLL)) wwaass aaddddeedd L LiiOOHH ((11 ..3333 gg,, 5555
- AAfftteerr eevvaappoorraatitioonn ooff EEttOOHH tthhee rreessiidduuee wwaass aacciiddiiffiieedd wwiitthh 22 NN aaqq.. HHCC11 uunnttiill ppHH 55--66,, aanndd tthheenn eexxttrraacctteedd wwiitthh EEttOOAAcc ttwwiiccee..
- ⁇ --NNMMRR ((DDMMSSOO--ddee,, VV '' aarriiaann,, 440000 MMHHzz)):: ⁇ 11..8899--22..2200 ((33HH,, mm)),, 22..4400--22..5500 ( (IIHH,, mm)),, 33..6611--33..8822 ((1IHH,, mm)),, 33..9922--44..0088 ((IIHH,, mm)),, 55..2244--55..4488 ( (1i Hl l,.
- Step B 5-chloropyrazolo[l,5-a]pyrimidine
- Step C 5-chloropyrazolo[l ,5-a]pyrimidine-3-carbaldehyde
- Step A (R)-5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)-N'-isobutyrylpyrazolo[l,5- a]pyrimidine-3-carbohydrazide
- Step B (R)-2-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3-yl)- 5-isopropyl-l,3,4-thiadiazole
- Step A (R)-5-(5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolo[l ,5-a]pyrimidin-3-yl)- 1 ,3,4-oxadiazol-2-amine
- Step B (R)-2-bromo-5-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5- a]pyrimidin-3 -yl) ⁇ 1 , 3 ,4-oxadiazole
- Step C (R)-tert-butyl 4-(5-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5- a]pyrimidin-3-yl)-l,3,4-oxadiazol-2-yl)piperazine-l-carboxylate
- Step A (R)-5-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3-yl)-
- Step B (R)-2-bromo-5-(5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolof 1 ,5- a]pyrimidin-3-yl)-l,3,4-oxadiazole
- Step C (R)-2-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3-yl)- 5-(l.H-pyrazol-4-yl)- 1 ,3,4-thiadiazole
- Step A tert-butyl 4-(hydrazinecarbonyl)piperidine-l-carboxylate
- hydrazine hydrate 5.84 g, 117 mmol
- Step B (R)-tert-butyl 4-(2-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5- a]pyrimidine-3-carbonyl)hydrazinecarbonyl)piperidine-l-carboxylate
- Step A (RVethyl 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-l- yl)pyrazolo[ 1 ,5-a]pynmidine-3-carboxylate
- Step B 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-l-yl)pyrazolo[l,5- a]pyrimidine-3-carboxylic acid
- Step C 5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin- 1 -y 1)-N'- aloylpyrazolo[l ,5-a]pyi"imidine-3-c "bohydrazide
- Step B 5-((2S,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-l -yl)pyrazolo[l,5- a]pyrimidine-3-carboxylic acid
- Step D 2-tert-butyl-5-(5-((2S,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-l- yl)pyrazolo[ 1 , 5 -a] pynmidm-3 -yl)- 1 , 3 ,4-oxadiazole
- Step A Ethyl 5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-l -yl)pyrazolo[ 1 imidine- 3 -carboxylate
- Step B 5-(2-(5-fluoro-2-rnethoxypyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidine- 3-carboxylic acid
- Step C 5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-l-yl)-N'-pivaloylpyrazolo[l,5- a]pyrimidine- 3 -carbohydrazide
- Step D 2-tert-butyl-5-(5-(2-(5-fluoro-2-methoxypyridin-3-yl)pyrrolidin-l- yl)pyrazolo[l,5-a]pyrimidin-3-yl)-l,3, -oxadiazole
- Step B 5-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3- yl)oxazole
- Step A 5-chloro-3-iodopyrazolo[l ,5-a]pyrimidine
- Step B 5-(2-(2,5-difluorophenyl) rrolidin-l-yl)-3-iodopyrazolo[l,5-a]pyrimidine
- Step C 4-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3- yl)isoxazole
- Step A 5-oxo-4,5-dihydropyrazolo[ l,5-a]pynmidine-3-cafbonitrile
- Step B 5-chloropyrazolo[ 1 ,5-a]pyrimidine-3-carbonitrile
- Step C 5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidine-3- carbonitrile
- Step D 5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidine-3- carboxamide
- Step E (Z)-5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)-N-(l-(dimethylamino)ethylidene)- pyrazolo[ 1 , 5-a]pyrimidine-3-carboxamide
- Step F 5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)-3-(5-methyl-lH-l ,2,4-triazol-3- yl)pyrazolo[ 1 , 5 -a] pyrimidine
- Step A (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolo[l ,5-a]pyrimidine
- Step B (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)-3-iodopyrazolo[l,5-a]pyrimidine
- Step C (R)-5-(2-(2,5-difiuorophenyl)pyrrolidin-
- Step A tert-but l 4-hydroxypiperidine-l -carboxylate
- Step B tert-butyl 4-(methylsulfonyloxy)piperidine-l -carboxylate c
- Step C tert-butyl 4-azidopiperidme-l -carboxyiate
- Step D (R)-tert-butyl 4-(4-(5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolo[l ,5- a]pyrimidin-3 -yl)- 1H- 1 ,2,3-triazol- -yl)piperidine- 1 -carboxyiate
- reaction mixture was cooled to room temperature and diluted with EtOAc. After addition of cone. NH 4 OH (2.0 mL) followed by water (2.0 mL), the mixture was vigorously stirred for 30 min and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na 2 S04, filtered and concentrated in vacuo.
- Step E (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)-3-(l-(piperidin-4-yl)-lH-l ,2,3- triazol-4-yl)pyrazolo[l,5-a]pyrimidin
- Step A tert-butyl 3-(methylsulfonyloxy)piperidine-l-carboxylate
- Step B tert-butyl 3-azidopiperidine-l-carboxylate
- Step C tert-butyl 3-(4-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5- a]pyrimidin-3 -yl)- 1 H- 1 ,2, 3 -triazol- -yl)piperidine- 1 -carboxylate
- Step D 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-l-yl)-3-(l-(piperidin-3-yl)-lH-l,2,3- triazol -4-yl)pyrazolo[ , 5-a]pyrimidin
- Step A tert-but l 3-(methylsulfonyloxy)pyrrolidine-l-carboxylate
- Step B tert-butyl 3-azidopyrrolidine-l-carboxylate
- Step C tert-butyl 3-(4-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolo[l,5- a]pyrimidin-3-yl)- 1H- 1 ,2,3-triazol- -yl)pyrrolidine- 1 -carboxylate
- reaction mixture was cooled to room temperature and then diluted with EtOAc. After addition of cone. NH 4 OH (2.0 mL) followed by water (2.0 mL), the mixture was vigorously stirred for 30 min and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na?S0 4 , filtered and concentrated in vacuo.
- Step D 5-((R)-2-(2,5-difluorophenyl)pyrrolidin-l -yl)-3-(l -(pyrrolidin-3-yl)-lH-l,2,3- triazol-4-yl)pyrazolo[l,5-a]pyrimidine
- Step C (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)-3-(l-(tetrahydro-2H-pyran-4'
- Step A tert-butyl 4-(2-bromoacetyl)piperazine-l-carb
- Step B tert-butyl 4-(2-azidoacet l)piperazine-l -carboxylate
- Step C tert-butyl (R)-4-(2-(4-(5-(2-(2,5-difluorophenyl)pyrrolidin-l -yl)pyrazolo[l ,5- a]pyrimidin-3-yl)- lH-1 ,2,3-triazol- -yl)acetyl)piperazine- 1 -carboxylate
- Step D (R)-2-(4-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3- yl)- 1 H- 1 ,2,3 -triazol- 1 -yl)- 1 -(piperazin- 1 -yl)ethan- 1 -one
- Step A 5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l -yl)pyrazolo[l ,5-a]pyrimidine-3- carbaldehvde
- Step B (E)-eihyl-3-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrirnidin-
- Step C (E)-3-(5-(2-(5-fluoropyridin-3-yl)pyiTolidin-l-yl)pyrazolo[l,5-a]pyrimidin-3- yl)acrylic acid
- Step D (E)-N-ethyl-3-(5-(2-(5-fluoropyridin-3-yl)pyrrolidin-l -yl)pyrazolo[l,5- a]pyrimidin-3-yl)acrylamide
- Step B (E)-ethyl-3-(5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-
- Step C (E)-3-(5-(2-(2,5-difluorophenyl)pyrrolidin- 1 -yl)pyrazolo[ 1 ,5-a]pyrimidin-3- yl)acrylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015365587A AU2015365587B2 (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as TRK inhibitors |
CN201580075880.1A CN107207514B (en) | 2014-12-15 | 2015-12-14 | Fused heteroaryl compounds and their use as TRK inhibitors |
FIEP15869420.8T FI3233863T3 (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors |
KR1020247012821A KR20240055170A (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors |
RU2017125025A RU2708674C2 (en) | 2014-12-15 | 2015-12-14 | Condensed ring heteroaryl compounds and use thereof as trk inhibitors |
KR1020177018519A KR102659741B1 (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors |
EP15869420.8A EP3233863B1 (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors |
EP24169331.6A EP4420732A2 (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors |
MX2017007748A MX2017007748A (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors. |
CA2971024A CA2971024C (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors |
BR112017012755-5A BR112017012755B1 (en) | 2014-12-15 | 2015-12-14 | TRK INHIBITOR FUSED RING HETEROARYL COMPOUNDS |
JP2017533343A JP6609631B2 (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and uses as TRK inhibitors |
DK15869420.8T DK3233863T3 (en) | 2014-12-15 | 2015-12-14 | FUSED RING HETERORAYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462092193P | 2014-12-15 | 2014-12-15 | |
US62/092,193 | 2014-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016097869A1 true WO2016097869A1 (en) | 2016-06-23 |
WO2016097869A4 WO2016097869A4 (en) | 2016-08-04 |
Family
ID=56110505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/002521 WO2016097869A1 (en) | 2014-12-15 | 2015-12-14 | Fused ring heteroaryl compounds and their use as trk inhibitors |
Country Status (13)
Country | Link |
---|---|
US (1) | US9701681B2 (en) |
EP (2) | EP4420732A2 (en) |
JP (1) | JP6609631B2 (en) |
KR (2) | KR20240055170A (en) |
CN (1) | CN107207514B (en) |
AU (1) | AU2015365587B2 (en) |
BR (1) | BR112017012755B1 (en) |
CA (1) | CA2971024C (en) |
DK (1) | DK3233863T3 (en) |
FI (1) | FI3233863T3 (en) |
MX (1) | MX2017007748A (en) |
RU (1) | RU2708674C2 (en) |
WO (1) | WO2016097869A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018081417A3 (en) * | 2016-10-26 | 2018-06-07 | Qian Zhao | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
WO2018152134A1 (en) * | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Proline-based neuropeptide ff receptor modulators |
US10246466B2 (en) | 2014-01-24 | 2019-04-02 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
CN109593803A (en) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | (R) preparation method of -2- (2,5- difluorophenyl) pyrrolidines or its salt |
US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
CN109890820A (en) * | 2016-10-28 | 2019-06-14 | 正大天晴药业集团股份有限公司 | Amino-pyrazol as neurotrophic factor tyrosine kinase receptor inhibitor and pyrimidine compound |
WO2019118584A1 (en) * | 2017-12-15 | 2019-06-20 | Pyramid Biosciences, Inc. | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
US10590139B2 (en) | 2008-09-22 | 2020-03-17 | Array Biopharma Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US10588908B2 (en) | 2016-04-04 | 2020-03-17 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10647730B2 (en) | 2010-05-20 | 2020-05-12 | Array Biopharma Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US10655186B2 (en) | 2015-10-26 | 2020-05-19 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10668072B2 (en) | 2016-04-04 | 2020-06-02 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
WO2020114499A1 (en) * | 2018-12-07 | 2020-06-11 | Betta Pharmaceuticals Co., Ltd | Tyrosine kinase inhibitors, compositions and methods there of |
US10688100B2 (en) | 2017-03-16 | 2020-06-23 | Array Biopharma Inc. | Macrocylic compounds as ROS1 kinase inhibitors |
CN111362946A (en) * | 2018-12-25 | 2020-07-03 | 上海度德医药科技有限公司 | Pharmaceutical compound and composition and application thereof |
US10758542B2 (en) | 2009-07-09 | 2020-09-01 | Array Biopharma Inc. | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors |
US10774085B2 (en) | 2008-10-22 | 2020-09-15 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
WO2021083345A1 (en) * | 2019-10-30 | 2021-05-06 | 先声药业有限公司 | Preparation method for pyrazolopyrimidine compound and intermediate thereof |
WO2021211882A1 (en) * | 2020-04-15 | 2021-10-21 | Pyramid Biosciences, Inc. | Methods for preparing tyrosine receptor kinase inhibitors |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
KR20220064248A (en) | 2020-11-11 | 2022-05-18 | 주식회사 한독 | A manufacturing method of TRK inhibitor compounds |
EP3932923A4 (en) * | 2019-03-19 | 2022-06-01 | Central China Normal University | Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor |
US11459332B2 (en) | 2018-03-14 | 2022-10-04 | Fochon Biosciences, Ltd. | Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors |
RU2781618C2 (en) * | 2018-03-14 | 2022-10-14 | Фочон Байосайенсис, Лтд. | Substituted (2-azabicyclo[3.1.0]hexane-2-yl)pyrazolo[1.5-a]pyrimidine and imidazo[1.2-b]pyridazine compounds as trk kinase inhibitors |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2995997A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
CN108431008A (en) | 2015-11-19 | 2018-08-21 | 蓝图药品公司 | It can be used for treating the compound and composition with the relevant illnesss of NTRK |
US10738033B2 (en) | 2017-05-31 | 2020-08-11 | Nantbio, Inc. | Trk inhibition |
US10800760B2 (en) | 2017-05-31 | 2020-10-13 | Nantbio, Inc. | Trk inhibition |
MA50456A (en) | 2017-10-26 | 2020-09-02 | Array Biopharma Inc | MACROCYCLIC KINASE TRK INHIBITOR FORMULATIONS |
CN108218754B (en) * | 2018-01-23 | 2021-05-07 | 广东赛烽医药科技有限公司 | Preparation method of 2- (2,5-difluorophenyl) pyrrolidine |
JP7323748B2 (en) * | 2018-02-28 | 2023-08-09 | ナンジン ザイミン ファーマシューティカル カンパニー リミテッド | Pyrazolopyrimidine derivative and use thereof |
CA3095366A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
CN108484361B (en) * | 2018-05-11 | 2022-09-30 | 弈柯莱生物科技(上海)股份有限公司 | (S) -4-chloro-1- (2,5) -difluorophenylbutan-1-ol and preparation method and application thereof |
CN110294761B (en) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | Substituted pyrazolo [1,5-a ] pyrimidine compounds as Trk kinase inhibitors |
WO2019233461A1 (en) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Tropomyosin receptor kinase inhibitor, preparation method therefor and use thereof |
CN110577532B (en) | 2018-06-08 | 2022-06-03 | 江苏威凯尔医药科技有限公司 | Tropomyosin receptor kinase inhibitor and preparation method and application thereof |
GB201811825D0 (en) | 2018-07-19 | 2018-09-05 | Benevolentai Bio Ltd | Organic compounds |
CN108794370A (en) * | 2018-07-31 | 2018-11-13 | 上海弈柯莱生物医药科技有限公司 | A kind of preparation method for drawing sieve to replace Buddhist nun's intermediate |
CN110857304B (en) * | 2018-08-24 | 2021-05-18 | 北京富龙康泰生物技术有限公司 | Trk inhibitor, preparation method and application thereof |
CN109053525B (en) * | 2018-09-25 | 2020-05-05 | 成都福柯斯医药技术有限公司 | Preparation method of (R) -2- (2-substituted-5-fluorobenzene) pyrrolidine |
EP3866789A4 (en) * | 2018-10-15 | 2022-07-06 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
CN111138333B (en) * | 2018-11-02 | 2023-05-23 | 上海复星星泰医药科技有限公司 | Preparation method of (R) -2- (2, 5-difluorophenyl) -pyrrolidine |
CN111302995A (en) * | 2018-12-12 | 2020-06-19 | 上海复星星泰医药科技有限公司 | Preparation method of 2- (2, 5-difluorophenyl) -pyrrolidine racemate |
JP7420403B2 (en) * | 2019-05-08 | 2024-01-23 | ティーワイケー メディシンズ インコーポレーテッド | Compounds used as kinase inhibitors and their applications |
CN114258394B (en) * | 2019-08-28 | 2024-04-23 | 南京再明医药有限公司 | Crystal form of oncogenic fusion kinase inhibitor and application thereof |
CN112979654B (en) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业(成都)有限公司 | Heteroaryl fused ring compounds, preparation method and application thereof |
CA3163585A1 (en) | 2020-01-22 | 2021-07-29 | Benevolentai Bio Limited | Pharmaceutical compositions and their uses |
CN111302997B (en) * | 2020-04-15 | 2022-03-29 | 江苏恒沛药物科技有限公司 | Method for preparing Raatinib intermediate by one-pot method |
CN111393347B (en) * | 2020-04-30 | 2020-11-17 | 安徽德信佳生物医药有限公司 | Synthetic method of ralotinib intermediate |
CN115551863A (en) * | 2020-06-11 | 2022-12-30 | 贝达药业股份有限公司 | Salt form, crystal form, pharmaceutical composition and application of tyrosine kinase inhibitor |
CN114437075A (en) * | 2020-11-03 | 2022-05-06 | 上海瑶琪生物科技有限公司 | Compounds useful as inhibitors of NTRK kinase and uses thereof |
CN116102464A (en) * | 2021-11-10 | 2023-05-12 | 凯特立斯(深圳)科技有限公司 | Method for preparing amino alcohol by asymmetric hydrogenation and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011006074A1 (en) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
WO2011029027A1 (en) | 2009-09-03 | 2011-03-10 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010012457A (en) * | 2008-05-13 | 2010-12-07 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors. |
BRPI0919873B8 (en) | 2008-10-22 | 2021-05-25 | Array Biopharma Inc | substituted pyrazol[1,5-a]pyrimidine compounds as trk kinase inhibitors, their preparation processes and pharmaceutical compositions |
AU2009308675A1 (en) * | 2008-10-31 | 2010-05-06 | Genentech, Inc. | Pyrazolopyrimidine JAK inhibitor compounds and methods |
NZ630721A (en) * | 2012-03-09 | 2016-12-23 | Lexicon Pharmaceuticals Inc | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
-
2015
- 2015-12-14 EP EP24169331.6A patent/EP4420732A2/en active Pending
- 2015-12-14 RU RU2017125025A patent/RU2708674C2/en active
- 2015-12-14 EP EP15869420.8A patent/EP3233863B1/en active Active
- 2015-12-14 US US14/968,208 patent/US9701681B2/en active Active
- 2015-12-14 WO PCT/IB2015/002521 patent/WO2016097869A1/en active Application Filing
- 2015-12-14 FI FIEP15869420.8T patent/FI3233863T3/en active
- 2015-12-14 DK DK15869420.8T patent/DK3233863T3/en active
- 2015-12-14 CA CA2971024A patent/CA2971024C/en active Active
- 2015-12-14 MX MX2017007748A patent/MX2017007748A/en unknown
- 2015-12-14 KR KR1020247012821A patent/KR20240055170A/en active Search and Examination
- 2015-12-14 CN CN201580075880.1A patent/CN107207514B/en active Active
- 2015-12-14 AU AU2015365587A patent/AU2015365587B2/en active Active
- 2015-12-14 JP JP2017533343A patent/JP6609631B2/en active Active
- 2015-12-14 KR KR1020177018519A patent/KR102659741B1/en active IP Right Grant
- 2015-12-14 BR BR112017012755-5A patent/BR112017012755B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011006074A1 (en) | 2009-07-09 | 2011-01-13 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
WO2011029027A1 (en) | 2009-09-03 | 2011-03-10 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
Non-Patent Citations (36)
Title |
---|
"Method in Enzymology", vol. 42, 1985, ACADEMIC, pages: 309 - 396 |
BARDELLI, A, SCIENCE, vol. 300, 2003, pages 949 |
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
BRODEUR, G.M., NAT. REV. CANCER, vol. 3, 2003, pages 203 - 216 |
BUNDGAARD, H., ADVANCED DRUG DELIVERY REVIEW, vol. 8, 1992, pages 1 - 38 |
BUNDGAARD, H: "VOGEL'S ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY", 1991, LONGMAN SCIENTIFIC AND TECHNICAL LTD., article "Design and Application of Prodrugs", pages: 113 - 191 |
CAREYSUNDBERG: "ADVANCED ORGANIC CHEMISTRY", vol. A,B, 2000, PLENUM PRESS |
DANG ET AL., J OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 21, no. 5, 2006, pages 850 - 858 |
DELAFOY, L ET AL., PAIN, vol. 105, 2003, pages 489 - 497 |
DI MOLA, F.F, GUT, vol. 46, no. 5, 2000, pages 670 - 678 |
DIONNE ET AL., CLIN. CANCER RES., vol. 4, no. 8, 1998, pages 1887 - 1898 |
DOU, Y.C., ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 298, no. 1, 2006, pages 31 - 37 |
ERIC ADRIAENSSENS, E ET AL., CANCER RES, vol. 68, no. 2, 2008, pages 346 - 351 |
FREUND-MICHEL, V, PHARMACOLOGY & THERAPEUTICS, vol. 117, no. 1, 2008, pages 52 - 76 |
GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 1996, MACK PUBLISHING CO. |
HELLER, ACC. CHEM. RES., vol. 23, 1990, pages 128 |
HU VIVIAN Y, THE JOURNAL OF UROLOGY, vol. 173, no. 3, 2005, pages 1016 - 1021 |
JAGGAR, S.I. ET AL., BR. J. ANAESTH., vol. 83, 1999, pages 442 - 448 |
KRUETTGEN ET AL., BRAIN PATHOLOGY, vol. 16, 2006, pages 304 - 310 |
LAMB, K ET AL., NEUROGASTROENTEROL. MOTIL., vol. 15, 2003, pages 355 - 361 |
LI, C.-Q. ET AL., MOLECULAR PAIN, vol. 4, no. 28, 2008, pages 1 - 11 |
MA, Q.P.WOOLF, C. J., NEUROREPORT, vol. 8, 1997, pages 807 - 810 |
MARCHETTI ET AL., HUMAN MUTATION, vol. 29, no. 5, 2008, pages 609 - 616 |
MATAYOSHI, S., J. PHYSIOL., vol. 569, 2005, pages 685 - 695 |
MCMAHON, S.B. ET AL., NAT. MED., vol. 1, 1995, pages 774 - 780 |
MEYER, J. ET AL., LEUKEMIA, 2007, pages 1 - 10 |
NAKAGAWARA, A, CANCER LETTERS, vol. 169, 2001, pages 107 - 114 |
PATAPOUTIAN, A ET AL., CURRENT OPINION IN NEUROBIOLOGY, vol. 11, 2001, pages 272 - 280 |
PIEROTTIA, M.A., GRECO A. CANCER LETTERS, vol. 232, 2006, pages 90 - 98 |
RAYCHAUDHURI, S.P., J. INVESTIGATIVE DERMATOLOGY, vol. 122, no. 3, 2004, pages 812 - 819 |
SHELTON, D.L. ET AL., PAIN, vol. 116, 2005, pages 8 - 16 |
SOHRABJI, F, NEUROENDOCRINOLOGY, vol. 27, no. 4, 2006, pages 404 - 414 |
THOMPSON, S.W., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 7714 - 7718 |
VAISHNAVI, A, NATURE MEDISINE, vol. 19, no. 11, 2013, pages 1469 - 1472 |
WOOLF, C.J. ET AL., NEUROSCIENCE, vol. 62, 1994, pages 327 - 331 |
ZAHN, P.K. ET AL., J. PAIN, vol. 5, 2004, pages 157 - 163 |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10590139B2 (en) | 2008-09-22 | 2020-03-17 | Array Biopharma Inc. | Method of treatment using substituted imidazo[1,2b]pyridazine compounds |
US10774085B2 (en) | 2008-10-22 | 2020-09-15 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
US11267818B2 (en) | 2008-10-22 | 2022-03-08 | Array Biopharma Inc. | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
US10758542B2 (en) | 2009-07-09 | 2020-09-01 | Array Biopharma Inc. | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors |
US10647730B2 (en) | 2010-05-20 | 2020-05-12 | Array Biopharma Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US10246466B2 (en) | 2014-01-24 | 2019-04-02 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
US10618912B2 (en) | 2014-01-24 | 2020-04-14 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10813936B2 (en) | 2014-11-16 | 2020-10-27 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
US10907215B2 (en) | 2015-10-26 | 2021-02-02 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10655186B2 (en) | 2015-10-26 | 2020-05-19 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
US10588908B2 (en) | 2016-04-04 | 2020-03-17 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US10668072B2 (en) | 2016-04-04 | 2020-06-02 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11191766B2 (en) | 2016-04-04 | 2021-12-07 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
US11484535B2 (en) | 2016-04-04 | 2022-11-01 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
CN110267958A (en) * | 2016-10-26 | 2019-09-20 | 阿雷生物药品公司 | The method for preparing pyrazolo [1,5-a] pyrimidine and its salt |
US11091486B2 (en) | 2016-10-26 | 2021-08-17 | Array Biopharma, Inc | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof |
WO2018081417A3 (en) * | 2016-10-26 | 2018-06-07 | Qian Zhao | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
CN109890820B (en) * | 2016-10-28 | 2020-11-03 | 正大天晴药业集团股份有限公司 | Aminopyrazolopyrimidine compounds as neurotrophin tyrosine kinase receptor inhibitors |
CN109890820A (en) * | 2016-10-28 | 2019-06-14 | 正大天晴药业集团股份有限公司 | Amino-pyrazol as neurotrophic factor tyrosine kinase receptor inhibitor and pyrimidine compound |
KR102616249B1 (en) * | 2016-10-28 | 2023-12-21 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Amino pyrazolopyrimidine compounds used as neurotrophic factor tyrosine kinase receptor inhibitors. |
EP3533796A4 (en) * | 2016-10-28 | 2020-06-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
US10829492B2 (en) | 2016-10-28 | 2020-11-10 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
KR20190067913A (en) * | 2016-10-28 | 2019-06-17 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Aminopyrazolopyrimidine compounds used as inhibitors of tyrosine kinase receptors which are neurotrophic factors |
RU2764523C2 (en) * | 2016-10-28 | 2022-01-18 | Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. | Aminopyrazolopyrimidine compound used as inhibitor of tyrosine kinase receptor of neurotrophic factor |
AU2017348826B2 (en) * | 2016-10-28 | 2021-12-02 | Centaurus Biopharma Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
US11826350B2 (en) | 2017-02-14 | 2023-11-28 | Research Triangle Institute | Proline-based neuropeptide FF receptor modulators |
US11491136B2 (en) | 2017-02-14 | 2022-11-08 | Research Triangle Institute | Proline-based neuropeptide FF receptor modulators |
WO2018152134A1 (en) * | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Proline-based neuropeptide ff receptor modulators |
US10688100B2 (en) | 2017-03-16 | 2020-06-23 | Array Biopharma Inc. | Macrocylic compounds as ROS1 kinase inhibitors |
US10966985B2 (en) | 2017-03-16 | 2021-04-06 | Array Biopharma Inc. | Macrocyclic compounds as ROS1 kinase inhibitors |
WO2019005796A1 (en) * | 2017-06-26 | 2019-01-03 | Qian Zhao | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
JP2021506954A (en) * | 2017-12-15 | 2021-02-22 | ピラミッド バイオサイエンシズ インコーポレイテッド | 5- (2- (2,5-difluorophenyl) pyrrolidine-1-yl) -3- (1H-pyrazole-1-yl) pyrazolo [1,5] as a TRK kinase inhibitor for the treatment of cancer -A] Pyrimidine derivatives and related compounds |
TWI848925B (en) * | 2017-12-15 | 2024-07-21 | 美商金字塔生技公司 | Tropomyosin kinase inhibitors |
US11230546B2 (en) * | 2017-12-15 | 2022-01-25 | Pyramid Biosciences, Inc | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
JP7321183B2 (en) | 2017-12-15 | 2023-08-04 | ピラミッド バイオサイエンシズ インコーポレイテッド | 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5] as TRK kinase inhibitors for treating cancer -A] pyrimidine derivatives and related compounds |
US20230124248A1 (en) * | 2017-12-15 | 2023-04-20 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo [1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
AU2018383571B2 (en) * | 2017-12-15 | 2023-09-21 | Pyramid Biosciences, Inc. | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1H-pyrazol-1-yl)pyrazolo(1,5-a)pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
US11739096B2 (en) * | 2017-12-15 | 2023-08-29 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
EP4053128A1 (en) * | 2017-12-15 | 2022-09-07 | Pyramid Biosciences, Inc. | 5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
WO2019118584A1 (en) * | 2017-12-15 | 2019-06-20 | Pyramid Biosciences, Inc. | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
US11459332B2 (en) | 2018-03-14 | 2022-10-04 | Fochon Biosciences, Ltd. | Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors |
RU2781618C2 (en) * | 2018-03-14 | 2022-10-14 | Фочон Байосайенсис, Лтд. | Substituted (2-azabicyclo[3.1.0]hexane-2-yl)pyrazolo[1.5-a]pyrimidine and imidazo[1.2-b]pyridazine compounds as trk kinase inhibitors |
EP3891152A4 (en) * | 2018-12-07 | 2022-09-07 | Betta Pharmaceuticals Co., Ltd | Tyrosine kinase inhibitors, compositions and methods there of |
WO2020114499A1 (en) * | 2018-12-07 | 2020-06-11 | Betta Pharmaceuticals Co., Ltd | Tyrosine kinase inhibitors, compositions and methods there of |
CN109593803A (en) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | (R) preparation method of -2- (2,5- difluorophenyl) pyrrolidines or its salt |
CN111362946A (en) * | 2018-12-25 | 2020-07-03 | 上海度德医药科技有限公司 | Pharmaceutical compound and composition and application thereof |
EP3932923A4 (en) * | 2019-03-19 | 2022-06-01 | Central China Normal University | Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor |
WO2021083345A1 (en) * | 2019-10-30 | 2021-05-06 | 先声药业有限公司 | Preparation method for pyrazolopyrimidine compound and intermediate thereof |
CN115515591A (en) * | 2020-04-15 | 2022-12-23 | 派拉米德生物科学公司 | Process for preparing tyrosine receptor kinase inhibitors |
WO2021211882A1 (en) * | 2020-04-15 | 2021-10-21 | Pyramid Biosciences, Inc. | Methods for preparing tyrosine receptor kinase inhibitors |
KR20220064248A (en) | 2020-11-11 | 2022-05-18 | 주식회사 한독 | A manufacturing method of TRK inhibitor compounds |
Also Published As
Publication number | Publication date |
---|---|
EP4420732A2 (en) | 2024-08-28 |
JP2017538766A (en) | 2017-12-28 |
AU2015365587B2 (en) | 2020-07-23 |
FI3233863T3 (en) | 2024-07-10 |
KR102659741B1 (en) | 2024-04-23 |
RU2017125025A3 (en) | 2019-06-21 |
US9701681B2 (en) | 2017-07-11 |
JP6609631B2 (en) | 2019-11-20 |
EP3233863A1 (en) | 2017-10-25 |
DK3233863T3 (en) | 2024-07-15 |
MX2017007748A (en) | 2018-01-30 |
CN107207514A (en) | 2017-09-26 |
US20160168156A1 (en) | 2016-06-16 |
CN107207514B (en) | 2020-01-24 |
AU2015365587A1 (en) | 2017-08-03 |
RU2708674C2 (en) | 2019-12-11 |
BR112017012755A2 (en) | 2017-12-26 |
KR20170095919A (en) | 2017-08-23 |
CA2971024C (en) | 2023-09-26 |
BR112017012755B1 (en) | 2023-11-14 |
WO2016097869A4 (en) | 2016-08-04 |
CA2971024A1 (en) | 2016-06-23 |
RU2017125025A (en) | 2019-01-17 |
EP3233863B1 (en) | 2024-04-10 |
EP3233863A4 (en) | 2018-06-06 |
KR20240055170A (en) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015365587B2 (en) | Fused ring heteroaryl compounds and their use as TRK inhibitors | |
CA3090482C (en) | Tetrahydroquinazoline derivatives useful as anticancer agents | |
US11420968B2 (en) | Bcl-2 inhibitors | |
CN105732636B (en) | Heteroaromatic compounds and their use in medicine | |
CA3013618C (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
EA039783B1 (en) | TYROSINE AMIDE DERIVATIVES AS Rho KINASE INHIBITORS | |
EP2742049A1 (en) | Tricyclic heterocyclic compounds and jak inhibitors | |
AU2015323380B2 (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | |
CN102143746A (en) | CDK modulators | |
EA030472B1 (en) | PYRROLO[2,3-d]PYRIMIDINYL, PYRROLO[2,3-b]PYRAZINYL AND PYRROLO[2,3-d]PYRIDINYL ACRYLAMIDES | |
JP2010526138A (en) | Pyrrolopyrimidin-7-one derivatives and their use as drugs | |
EP4129996A1 (en) | Novel aminopyrimidine egfr inhibitor | |
KR20130002991A (en) | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds | |
JP2022517901A (en) | Cyclic urea | |
EP3638680B1 (en) | Heteroaromatic compounds as vanin inhibitors | |
EP3402789B1 (en) | Isoquinolones as btk inhibitors | |
AU2018334272A1 (en) | Tetrahydro-imidazo quinoline compositions as CBP/p300 inhibitors | |
AU2021377891A9 (en) | Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors | |
JP2023526839A (en) | Azetidine cyclic ureas | |
CN114761399B (en) | Imidazole carboxamide derivatives as bruton's tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15869420 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/007748 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2971024 Country of ref document: CA Ref document number: 2017533343 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017012755 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20177018519 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015869420 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017125025 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015365587 Country of ref document: AU Date of ref document: 20151214 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017012755 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170614 |